PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 1CLINICAL PROTOCOL
A RANDOMIZED COMPARATIVE STUDY ASSESSING THE SWITCHING 
BETWEEN PF-06410293 AND HUMIRA®IN COMBINATION WITH
METHOTREXATE IN PARTICIPANTS WITH MODERATELY TO SEVERELY 
ACTIVE RHEUMATOID ARTHRITIS 
Investigational Product Number: PF-[ADDRESS_705499] Name: [CONTACT_51101]-[COMPANY_007]
[LOCATION_002] (US) Investigational New 
Drug (IND) Number:
European Clinical Trials Database 
(EudraCT) Number:2019-000284-24
Protocol Number: B5381012
Phase: 3
Short Title:
A Comparative Study Between PF-06410293 And Humira in Combination with 
Methotrexate in Participants with Active Rheumatoid Arthritis 
This document and accompanying materials contain confidential information belonging to [COMPANY_007].  Except as 
otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289]) or 
use it for unauthorized purposes.  In the event of any actual or suspected breach of this obligation, [COMPANY_007] 
must be promptly notified.
CCI
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 2Protocol Amendment Summary of Changes Table
Document History
Document Version Date Summary of Changes and Rationale
Original protocol 28June 2019 Not applicable (N/A)
Amendment 1 19May 2020 Protocol Administrative Clarification 
Letters (P ACLs) were incorporated:
Women of Childbearing Potential 
(WOCBP) Contraceptive use after 
last study  dose is updated from “a 
minimum of 28 day s” to “at least 
5months” to follow the study ’s 
single reference safet y document 
(SRSD) , which is the Humira label
in Appendix 4.  
Typographic error corrected for 
white blood cell count, lymphocy te 
count and platelets lab tests listed 
in Exclusion Criteria 19.
Updated instruction on empty  drug 
containers in Sections 6.1.[ADDRESS_705500] accountability  purpose.
Text update in the protocol title :
“interchangeability  of” is replaced 
by“switching between”.
Week 22 injection site updated to 
abdomen instead of abdomen or 
either upper front thigh to support 
primary  data analysisin Schedule 
of Activities (SoA) , Table 1, 
Sections 6.1.1 and 6.1.2.
Alternative solutions that are onl y 
acceptable during the COVID -[ADDRESS_705501] been 
added in SoA, Sections 6.2.1, 6.4, 
7.1, 7.2 and Appendix 11.
PF-06410293
Protocol B5381012Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 3Document History
Document Version Date Summary of Changes and Rationale
Updated status of expecting PF-06410293 
approval as a biosimilar to Humira from Food and Drug Administration (FDA) and regulatory agencies to approval forPF-06410293 as a biosimilar to Humira was received from the FDA in 
Sections 1.1, 2, 2.2 and 2.3.
•Mention of marketing applications 
under review with other agency(s) 
is removed from Section 2.2.
Corrected participant’s age range from age of 18 and older to between age of 18 to 70 years in Section 1.1.
Corrected definition for end of Treatment Period (TP) [ADDRESS_705502] investigational dose at Week 32 in Sections 1.1 and 4.1.
Added clarification in Table 1, Sections 1.1, 4.1 and 8.5 that the 2-week pharmacokinetic (PK) sampling period starts with Week 30 predose PK collection and ends with predose PK collection at Week 32.
Added clarification in Section 1.1 that immune-related safety will be described for the safety population including injection site reactions, hypersensitivity, anaphylaxis and angioedema.
 
Added utilization of home healthcare service as an option during the 2 week PK CCI
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 4Document History
Document Version Date Summary of Changes and Rationale
sampling period in SoA, Table 1 and 
Section 8.5.
Clarified that only  applicable adalimumab 
injection details will be recorded in the 
electronic Participant Dosing Log in SoA, 
Sections 6.1.1 and 6.4.
Clarifications made tothe following 
inclusion/exclusion criteria to stay  
consistent with Humira label:
Removal of Inclusion Criteri on 7 
as it is a duplication of Exclusion 
Criteri on 14.  Additionally , 
clarification is made to Exclusion 
Criteri on 14. 
Clarification provided to 
Section 5.2, Exclusion Criteria 4c
and Section 8.2.[ADDRESS_705503] 
has been added.
Clarifi cation provided on 
prohibited biologic therapy  in 
Exclusion Criteri on 13, Section 6.5 
and Appendix 9 (Prohibited 
Concomitant Medication and 
Procedures) .
Added new Exclusion Criteri on 18
that unstable dose of oral and 
intramuscular (IM) corticosteroid is 
prohibited.  Updated Sections 6.5.2 
and removed Appendix 9 (Oral 
Corticosteriod in FAP) .
Add clarification to Exclusion Criterion 
(#3) that active significant infection, 
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 5Document History
Document Version Date Summary of Changes and Rationale
eg,SARS -CoV2 (COVID -19) infection 
and an y active infection considered to be 
clinically  significant b y the investigator 
should be excluded.  Updates are also 
made in Sections 7.1.1 and 7.1.2.
Language in Section 7.2 has been updated 
to follow [COMPANY_007]’s latest protocol template.
Updated population for analy sis in 
Section 9.3 and AE anal ysis in 
Section [IP_ADDRESS].
Updated contraceptive requirements to 
follow Humira label for male participants 
Section 10.4.1.  Additionally , removed text 
“highl y” from highly  effective 
contraceptive methods in Exclusion 
Criterion 24, Sections 5.3.[ADDRESS_705504] been added to follow [COMPANY_007]’s 
protocol template, as a result Section 8.5.1 
in protocol (28 June 2019) has been 
reformatted to Section 8.9.[ADDRESS_705505] OF TABLES ................................ ................................ ................................ ................... 10
1. PROTOCOL  SUMMARY ................................ ................................ ................................ ...11
1.1.Synopsis ................................ ................................ ................................ .................. 11
1.2. Schema ................................ ................................ ................................ .................... 16
1.3. Schedule of Activities (SoA) ................................ ................................ ................... 17
2. INTRODUCTION ................................ ................................ ................................ ............... 21
2.1. Study  Rationale ................................ ................................ ................................ .......22
2.2. Background ................................ ................................ ................................ ............. 22
2.2.1. Clinical Overview ................................ ................................ ....................... 22
2.3. Benefit/Risk Assessment................................ ................................ ......................... [ADDRESS_705506](s) Administered................................ ................................ .34
6.1.1. Administration ................................ ................................ ............................ 34
6.1.2. Training for Adalimumab Subcutaneous Injections...................................36
6.1.3. Medical Devices ................................ ................................ ......................... 36
6.2. Preparation/Handling/Storage/Accountability ................................ ........................ 36
6.2.1. Preparation and Dispensing ................................ ................................ ........ 38
6.3. Measures to Minimize Bias: Randomization and Blinding ................................ .....[ADDRESS_705507] ................................ ......................... 38
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 76.3.2. Breaking the Blind (Not Applicable) ................................ .......................... [ADDRESS_705508] Compliance ................................ ................................ .......39
6.5. Concomitant Therapy ................................ ................................ .............................. 39
6.5.1. Stable Background Therapi[INVESTIGATOR_014] ................................ ................................ .....41
[IP_ADDRESS]. Methotrexate ................................ ................................ .............. 41
[IP_ADDRESS]. Folic/Folinic Acid Supplements................................ ................ 41
[IP_ADDRESS]. Additional Background Therapi[INVESTIGATOR_014] ................................ ............ [ADDRESS_705509] AND 
PARTI CIPANT DI SCONTI NUAT ION/WITHDRAWAL ................................ ................ [ADDRESS_705510] ................................ ............................. 44
7.1.1. Temporary  Discontinuation ................................ ................................ ........ 45
7.1.2. Permanent Discontinuation ................................ ................................ ......... 45
7.2. Participant Discontinuation/Withdrawal From the Study ................................ .......[ADDRESS_705511] Radiograph ................................ ................................ ........................ 49
8.2.4. Electrocardiograms.....................................................................................49
8.2.5. Clinical Safety  Laboratory  Assessments ................................ .................... 49
8.2.6. QuantiFERON-TB Gold In- Tube Test ................................ ..................... 50
8.2.7. Pregnancy  Testing ................................ ................................ ...................... 50
8.2.8. Viral Disease Screening ................................ ................................ .............. 50
8.3. Adverse Events and Serious Adverse Events................................ .......................... 51
8.3.1. Time Period and Frequency  for Collecting AE and SAE Information .......51
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety ................................ ............... 52
PF-06410293
Protocol B5381012Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF...................52
8.3.2. Method of Detecting AEs and SAEs ..........................................................528.3.3. Follow-up of AEs and SAEs.......................................................................528.3.4. Regulatory Reporting Requirements for SAEs...........................................538.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational 
Exposure ..........................................................................................................53
[IP_ADDRESS]. Exposure During Pregnancy......................................................[IP_ADDRESS]. Exposure During Breastfeeding ................................................[IP_ADDRESS]. Occupational Exposure .............................................................54
8.3.6. Cardiovascular and Death Events...............................................................548.3.7. Medical Device Incidents (Including Malfunctions)..................................54
[IP_ADDRESS]. Time Period for Detecting Medical Device Incidents...............[IP_ADDRESS]. Follow-up of Medical Device Incidents....................................[IP_ADDRESS]. Prompt Reporting of Medical Device Incidents to Sponsor .....[IP_ADDRESS]. Regulatory Reporting Requirements for Medical Device 
Incidents ............................................................................................55
8.3.8. Medication Errors .......................................................................................55
8.4. Treatment of Overdose............................................................................................568.5. Pharmacokinetics ....................................................................................................578.6. Pharmaco dynamics..................................................................................................58
8.7. Genetics................................................................................................................... 58
8.7.1. Specified Genetics ......................................................................................588.7.2. Banked Biospecimens for Genetics ............................................................58
8.8. Biomarkers ..............................................................................................................58
8.8.1. Specified Gene Expression (RNA) Research .............................................588.8.2. Specified Protein Research .........................................................................588.8.3. Specified Metabolomic Research ...............................................................588.8.4. Banked Biospecimens for Biomarkers .......................................................58
8.9. Immunogenicity Assessments .................................................................................58
8.9.1. Analysis of Anti-adalimumab Antibodies and Neutralizing 
Anti-adalimumab Antibodies...........................................................................58
 
CCI
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 98.10. Health Economics ................................ ................................ ................................ .59
9. STATI STICAL CONSI DERATIONS ................................................................................59
9.1. Estimands and Statistical Hy potheses ................................ ................................ .....59
9.1.1. Estimands ................................ ................................ ................................ ....59
9.2. Sample Size Determination ................................ ................................ ..................... 59
9.3. Populations for Analysis ................................ ................................ ......................... 60
9.4. Statistical Analy ses................................ ................................ ................................ .60
9.4.1. E fficacy  Anal yses................................ ................................ ....................... 60
9.4.2. Safet y Anal yses................................ ................................ .......................... 61
[IP_ADDRESS]. Adverse Event ................................ ................................ ........... 61
[IP_ADDRESS]. Laboratory  Test Abnormalities ................................ ................. 61
[IP_ADDRESS]. Prior and Concomitant Mediations ................................ ........... 62
9.4.3. Other Anal yses................................ ................................ ............................ 62
[IP_ADDRESS]. Pharmacokinetics Analy sis................................ ....................... 62
[IP_ADDRESS]. ADA and NAb Analy sis................................ ............................ 62
[IP_ADDRESS]. Other Endpoint Analy sis................................ ........................... 62
9.5.Interim Anal yses................................ ................................ ................................ .....62
9.5.1. Data Monitoring Committee ................................ ................................ .......62
10. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS ................................ ................................ ................................ .......... 63
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ............... 63
10.1.1. Regulatory and Ethical Considerations ................................ .................... 63
[IP_ADDRESS]. Reporting of Safety  Issues and Serious Breaches of the 
Protocol or I CH GCP ................................ ................................ ......... 63
10.1.2. Financial Disclosure ................................ ................................ ................. 64
10.1.3. I nformed Consent Process ................................ ................................ ........ 64
10.1.4. Data Protection ................................ ................................ ......................... 65
10.1.5. Dissemination of Clinical Study  Data ................................ ...................... 65
10.1.6. Data Qualit y Assurance ................................ ................................ ............ 67
10.1.7. Source Documents ................................ ................................ .................... 68
10.1.8. Study  and Site Closure ................................ ................................ .............. 68
10.1.9. Sponsor’s Qualified Medical Personnel ................................ ................... 69
10.2. Appendix 2: Clinical Laboratory  Tests ................................ ................................ .70
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 1010.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ................................ ................................ ......71
10.3.1 . Definition of AE ................................ ................................ ....................... 71
10.3.2. Definition of SAE.....................................................................................72
10.3.3. Recording/Reporting and Follow- up of AEs and/or SAEs ....................... 73
10.3.4. Reporting of SAEs....................................................................................76
10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy  
Informa tion................................ ................................ ................................ ................ 78
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................78
10.4.2. Female Participant Reproductive Inclusion Criteria ................................ .78
10.4.3. Woman of Childbearing Potential (WOCBP) ................................ .......... 78
10.4.4. Contraception Methods ................................ ................................ ............. 79
10.5. Appendix 5: L iver Safety : Suggested Actions and Follow -up Assessments ........ 82
10.6. Appendix 6: ECG Findings of Potential Clinical Concern ................................ ...84
10.7. Appendix 7: Medical Device Incidents: Definition and Procedures for 
Recording, Evaluating, Follow- up, and Reporting ................................ .................... 86
10.8. Appendix 8: Country -Specific Requirements ................................ ....................... 88
10.9. Appendix 9: Prohibited Concomitant Medications and Procedures ..................... 89
10.10. Appendix 10: [LOCATION_001] Heart Associated Functional Classification 
Criteria................................ ................................ ................................ ....................... 90
10.11. Appendix 11: COVID -19 Pandemic Considerations ................................ .......... 91
10.12. Appendix 12: Abbreviations ................................ ................................ ............... [ADDRESS_705512] OF TABLES
Table 1. PK Sampling Table ................................ ................................ ................... 21
Table 2. Permitted Opi[INVESTIGATOR_2480]/Narcotic Drugs ................................ ............................. 42
Table3. Additional Opi[INVESTIGATOR_541141] y................................ .......... 43
Table 4. Protocol -Required Safet y Laboratory  Assessments ................................ .70
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 111.PROTOCOL SUMMARY 
1.1.Synopsis 
Short Title: A Comparative Study Between PF -06410293 And Humira in Combination 
with Methotrexate in Participants with Active Rheumatoid Arthritis
Rationale
Regulatory  approval forPF-06410293 as a biosim ilar to Humira was receiv ed from United 
States (US) FDA.  The purpose of conducting this trial is to support the application for the 
interchangeability  designation with the FDA, not to re -establish “PK equivalence” between 
licensed Humira and PF- 06410293.  The objectives and desig n of this study are consistent 
with recommendations for establishing interchangeability  (IC) found in the corresponding 
guidance.7
A designation of IC f or an approved biosimilar drug is granted by  [CONTACT_541158] ‘the risk in terms of safet y or diminished efficacy  of 
alternating or switching between use of the biological product and the reference product is 
not greater t han the risk of using the reference product without such alternation or switch’ 
(FDA Guidance, 2019).[ADDRESS_705513], interchange ability  means that 
“the biological product may  be substituted for the reference product without the intervention 
of the health care provider who prescribed the reference product”.[ADDRESS_705514], Humira. 
Objectives, Estimands, and Endpoints
Objectives Estimands Endpoints
Prim ary: Prim ary: Prim ary: 
To evaluate 
interchangeability of 
PF-06510293 and Humira 
by [CONTACT_541159] -state 
pharmacokinetics in a 
switching arm (following
3switches betw een Humira 
and PF -06410293) as 
compared to a 
non-switching arm 
(receiving only Humira).Evaluate the equivalence of 
primary endpoints (maximum 
observed concentration (C max) 
and area under the 
concentration -time curve over 
the dosing interval (AUC ) 
obtained during the intensive 
PK sampling interval) between 
the switching arm and 
non-switching arm in 
participants who meet the PK 
population criteria ,that include 
criteria for the number and 
timing of missing doses, 
availability of PK data, 
adherence to background 
therapy, and major protocol Cmaxand AUC obtained 
during the intensive PK 
sampling interval.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 12deviations related to PK 
assessment.
Objectives Estimands Endpoints
Secondary: Secondary: Secondary: 
To evaluate other serum 
adalimumab PK parameters 
in the switching arm and the 
non-switching arm.
To evaluate the overall 
safety and tolerability of the 
switching arm and the 
non-switching arm.
To evaluate
immunogenicity of the 
switching arm and the non -
switching arm .Summarize other serum 
adalimumab PK parameters , 
including time at which Cmax
occurs (Tmax), average 
concentration over the dosing 
interval (C av), and apparent 
clearance (CL/F) obtained 
during the intensive PK 
sampling interval in participants 
who meet the PK population 
criteria, and predose 
concentration during multiple 
dosing (Ctrough) obtained at 
scheduled PK sample 
timepoints in participants who 
meet the safety population 
criteria, for the switching arm 
and non -switching arm.
Summarize safety endpoints for 
the switching arm and 
non-switching arm in 
participants who meet the safety 
popul ation criteria.
Summarize percent of 
participants with antidrug 
antibodies (ADA), and 
neutralizing antibodies (NAb) 
and ADA/NAb titers over time 
for the switching arm and 
non-switching arm in 
participants who meet the 
Safety population criteria .Other serum adalimumab PK 
parameters, including T max, 
Cav, and CL/F obtained during 
the intensive PK sampling 
interval and Ctrough obtained at 
scheduled PK sample 
timepoints .
Safety measures characterized 
by [CONTACT_24975], incidence, severity, 
timing, seriousness and 
relatedness of 
treatment -emergent AEs and 
laboratory test abnormalities. 
Percent of participants with 
ADA/NAb and ADA/NAb 
titers over time. 
Overall Design
This is an open -label, [ADDRESS_705515] (IP) switching between the switching arm ( Humira and 
PF-06410293 ), as compared with non- switching arm ( Humira ). For purposes of this 
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 13protocol, the treatment arm that includes switches between PF -06410293 and Humira will be 
referred to as the “switching” arm, while the treatment arm that comprises continuous 
Humira treatment will be referred to as the “non -switching” arm.
The study  will include adult participants between the age of 18 and 70 years with moderate to 
severe rheumatoid arthritis (RA) who are on background methotrexate (MTX).  This study  
has two arms and comprises 3 switches in the switching arm, which has a total of four 
treatment periods (TP).  
TP1 (Lead In Period) will begin with the first dose of investigational product Humira
on Week 0 (Day  1) and conclude with the completion of Week 10pre-dose 
assessments. 
TP2 will begin with the 1:[ADDRESS_705516] dosing for 
Week 10 will begin after the randomization process in the respective treatment arms 
and will conclude with the completion of Week 16 pre-dose assessments.  
TP3 will begi n with investigational product dosing on Week 16, and conclude with 
the completion of Week 22 pre-dose assessments.  
TP4 will begin with investigational product dosing on Week [ADDRESS_705517] dosing is scheduled at Weeks 22, 24, 
26, 28, and 30, followed by  a 2-week PK sampling period from Week 30 to Week 32. 
TP4 will conclude with end of treatment ( EoT) assessments and final dose 
administration at Week 32.  
The 2 -week PK sampling period starts with Week 30 predose PK collection and ends 
with predose PK collection on Week 32.
Safety  Follow -Up Period begins after the last investigational product dosing on 
Week 32, and concludes at completion of the Week 36 assessments. All participants 
(including earl y discontinuations) will be followed for at least [ADDRESS_705518] dosing at the end of the PK 
sampling period and a 4 week safet y follow up.  The duration and details of each treatment 
period are described in the previous section.  
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 14Every  participant will receive adalimumab 40 mg to be administered subcutaneously  (SC) 
every  2weeks; on-site injections will occur at the clinic during scheduled visits. The first 
injection is to be administered at the site under t he supervision of the investigator or 
designee, where the participant and/or care giver will be assessed for their ability  to 
administer adalimumab. Any issues may  be reviewed at that time. The firstinjection should 
be an abdominal injection. Subsequently , the injection location may  be the abdomen or 
upper front of either thigh, unless otherwise specified in the Schedule of Activities (SoA) .
Following the first injection at the site, the participant should select a day  of the week to 
administer their investigational product injections at home every  other week, on the same 
day, except on the weeks where an onsite visit is scheduled .  Injections will occur during the 
scheduled visits under the supervision of the site’s inve stigator or designee.   Every  effort 
should be made for participants to return for the scheduled visits and investigational product 
administration within the visit windows outlined in the SoA to support the PK endpoints of 
this study .
Please refer to Section 6for additional investigational product information .
Data Monitoring Committee: 
This study  will not use a data monitoring committee (DMC) .
Statistical Methods
Pharmacokinetics
The serum concentrations between Week [ADDRESS_705519] non- compartmental analy sis to estimate the PK parameters for 
each individual p articipant. The PK parameters: maximum observed concentration (Cmax), 
area under the concentration -time curve over the dosing interval (AUC ), time at which C max
occurs (Tmax),average concentration (Cav),predose concentration during multiple dosing
(Ctrough),and apparent clearance (CL/F), and the serum concentrations will be summarized 
descriptivel y. 
Interchangeability will be assessed b y constructing the point estimate and the 
90% confidence intervals (CIs) for the geometric mean ratio ( GMR )for the primary  
endpoints C maxand AUC .  Interchangeability will be established statistically  if the 90% CI 
for the GMR is within (80.00%, 125.00%) for both endpoints.  The GMR and CI  will be 
obtained using anal ysis of variance (ANOVA) applied to log -transformed data, with terms 
for treatment and randomization stratification factors (weight categories).
Safety
Adverse Events will be summarized descriptively  using Safet y-TP1 population for Humira 
group in TP1 and using Safet y-Randomized populations for swi tching arm and 
non-switching arm during TP2 through TP4.  
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 15Immunogenicit y
For the ADA (antidrug antibodies) and NAb (neutralizing antibodies) data, the percentage of 
participants with positive ADA and NAb will be summarized for the safety -randomized 
population by  [CONTACT_541160].  For participants with positive ADA and 
NAb, the magnitude (titer), time of onset, and duration of ADA and NAb response will also 
be described.  In addition, immune -related safet y will be described for the safet y population 
including injection site reactions (ISR), h ypersensitivity , anaphy laxis, and angioedema.  
Efficacy
This study  will not evaluate efficacy .  
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 161.2.Schema
TP = Treatment Period.
TP [ADDRESS_705520] dose in 
the study
HumiraSafety 
Follow -Up
36 32
EotTP 1 (Lead In Period)
10 WeeksTP 4
10 Weeks
Week
0 10 22TP 2
6 weeks
Adalimumab Switches in Switching ArmRandomize
1:1 Ratio16
PK
PK
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 171.3.Schedule of Activities (SoA)
The SoA table provides an overview of the protocol visits and procedures.  Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to conduct eva luations or 
assessments required to protect the well -being of the participant. 
Study  related visits and procedures may  be disrupted during the Coronavirus Disease 2019 (COVID- 19) pandemic, please see 
Appendix 11 for alternative solutions, if applicable.
Study Period Scree
nTreat ment 
Period 1 
(Lead In)Treat ment
Period 2Treat men
t
Period 3Treat ment
Period 4Safety Follow up 
Visit Identifier 1 2
(BL)3 4 5 6 7 8 9 10 PK Profile 
Phlebotom y1411(EOT
/ET)161218
Study Week1-6to -1 0 4 10 16 22 24 26 28 30 30, 31 32 36
Study Day -42to -1 1 29 71 113 155 169 183 197 211 211 - 224 225 253
Visit Window in Days +7 7 7 7 7 7 7 7 [ 1] 1 +14
Informed Consent X
Inclusion/Exclusion Criteria X X
Contraception check X
Medical History X
Demography X
Prior Treatments for RA X
HIV, Hepatitis B & C2X
FSH3X
Tuberculosis Test4X
Chest Radiography5X
Single ECG (12 -Lead) X
Participant ID number (IWRS)6X
Randomization (IWRS)7X
Complete Physical Examination8X X16
Vital Signs9X X X X
Body Weight10X X X10X
PF-06410293
Protocol B5381012Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 18Study Period Scree
nTreatment 
Period 1 
(Lead In)Treatment
Period 2Treatmen
t
Period 3Treatment
Period 4Safety Follow up 
Visit Identifier 1 2
(BL)3 4 5 6 7 8 9 10 PK Profile 
Phlebotomy1411(EOT
/ET)161218
Study Week1-6 to -1 0 4 10 16 22 24 26 28 30 30, 31 32 36
Study Day -42 to -1 1 29 71 113 155 169 183 197 211 211 - 224 225 253
Visit Window in Days +7 ±7 ±7 ±7 ±7 ±7 ±7 ±7[ ±1] ±1 +14
Pregnancy Test11XX X
Contraception Verification X
Safety Laboratory Hematology X X X X
Chemistry X X X X
Urinalysis X X X X
Urine Drug screen X
ADA/NAb Samples12XX X X X X X X X
 
Drug Concentration Samples14XX X X X X X X X14
(7 samples)X
Adalimumab SC Injection15XX X X X X X X X X
Background Methotrexate and 
folic/folinic acidX X X X X X-----------------------------------------------------------------------------------------------X
Assessment of AEs17X X X X X X-----------------------------------------------------------------------------------------------X
Assessment of Concomitant 
Medications18X X X X X X-----------------------------------------------------------------------------------------------X
Abbreviations: ADA = Anti-drug Antibody; AE = Adverse Event; BL = Baseline; ECG = Electrocardiogram; EOT = End of Treatment Period; ET = Early  Termination; 
FSH = follicle stimulating hormone; HCG = human chorionic gonadotropin; HIV = Human Immunodeficiency Virus; ID = Identification; I WRS = InteractiveWeb-based response 
system; NAb = Neutralizing antibody; PK = Pharmacokinetics; ; SC = Subcutaneous. CCI
CCI
PF-06410293
Protocol B5381012Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 19Footnotes:
1. Visits should occur when scheduled, within the time window indicated in the column headings. When a visit does not happen on t he scheduled day within or outside the 
window, the next visit should still be on the initially scheduled calendar date to restore the original calendar. On investigat ional product dosing days, assessments and lab 
tests are to be performed prior to dosing unless otherwise stated. This will require special attention to ensure participants do  not administer the corresponding visit’s 
adalimumab injection prior to the clinic visit. Additional unscheduled assessments should be performed as clinically indicated.
2. Viral disease screening, including hepatitis screening (HBsAg, HBcAb, HBsAb, HCVAb and HCV RNA) and HIV screening (HIV-1 Ab an d HIV-2 Ab).  HIV screening 
(HIV-1 Ab and HIV-2 Ab) may be performed by [CONTACT_541161] a local lab (if required by [CONTACT_427]) at screening or wit hin [ADDRESS_705521] 12 consecutive months at the time of study screening w ith no alternative pathological or physiological 
cause.  A serum FSH level within the central laboratory’s reference range will confirm the participant’s non-childbearing statu s.
4. Tuberculosis test will use QuantiFERON®(QFT) – TB Gold In-Tube Test and must be performed within [ADDRESS_705522] be re-tested with QFT – TB Gold In-Tube Test and referred to a specialist (eg, pulmonologist, TB 
specialist or infectious disease specialist) for further evaluation of latent or active TB or false positive QFT test result, un less they have past history of having been adequately 
treated with appropriate chemoprophylaxis for latent TB or have completed treatment for active TB previously, in which case re- testing is not required.  Participants who test 
positive and are considered to have current latent TB can enroll in the study if they are on chemophrophylaxis for at least [ADDRESS_705523] radiography (lateral and posterior-anterior views) must be performed within a 12-week wi ndow prior to Screening.  If a chest computed tomography (CT) exam (or an 
alternative chest imaging) is performed within [ADDRESS_705524] x-ray is not required.
6. Individuals who do not meet the criteria for participation in this study (screen failure) within the 6 week screening period may be rescreened.
7. Participants completing Treatment Period 1 will be randomized into switching or non-switching treatment arms in a 1:1 ratio pri or to dosing on Week 10, stratified based on 
3 weight groups (Week 10 weight).  Participants randomized to the non-switching arm will continue on Humira for the remainder of  the study, and participants randomized to 
the switching arm will continue switching in each TP (TP2: PF-06410293; TP3: Humira; TP4: PF-06410293).
8. Complete physical exam (PE) of major body systems.  Additional targeted PE may be performed during the study at the investiga tor’s discretion, as indicated by [CONTACT_541162]. 
9. Vital signs include blood pressure, respi[INVESTIGATOR_541142], body temperature, body weight, with height measured at Screen ing only.  Blood pressure and pulse rate should 
be taken from the participant in the supi[INVESTIGATOR_541143] 5 minutes. 
10. Body weight (BW) for Randomization should use the one collected at Week 10.  Every effort should be made to obtain BW at Wee k 10 prior to randomization, however, if 
the Week 10 BW is not available, Screening or Baseline BW (whichever is closest to Week 10 visit) may be used to randomize.
11. Pregnancy testing at Screening in female participants of childbearing potential by [CONTACT_541163]. Pregnancy test ing (HCG) after Screening will be performed 
locally using urine samples. Pregnancy testing may be repeated more frequently if required by [CONTACT_1744]/ECs or local regulations, or if potential pregnancy is suspected.
12. Blood samples should be collected for ADA and NAb testing at the time when PK samples are also collected and prior to the ne xt investigational product administration. 
 CCI
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 2014. Please refer to Table 1(PK Sampling Table). ALL PK samples will be collected prior to study dose (pre-dose) at visits where onsite injection is scheduled .  Blood 
samples for determination of adalimumab trough drug concentrations will be collected within [ADDRESS_705525] administration on Weeks 22, 24, 26, 
28, and on Day 1 (time 0), Weeks [ADDRESS_705526] administration (ie,pre-dose) .
The [ADDRESS_705527] (PK Profile Day 1): blood will be collected 
within [ADDRESS_705528]-Week 30 d osing times for serum collections are 48 ( 4) hrs on PK 
Profile Day 3, 72 ( 6) hrs on PK Profile Day 4, 96 ( 8) hrs on PK Profile Day 5, 144 ( 8) hrs on PK Profile Day 7, 240 ( 24) hrs on PK Profile Day 11, and 336 (24) hrs on 
PK Profile Day 15. Every effort should be made to draw sam ples within the scheduled time points .  The [ADDRESS_705529] will be administered by [CONTACT_2299], care giver or site personnel every other week using pre -filled syringes provided by [CONTACT_456]; on-site 
injections will occur during every scheduled visits after PK and ADA/NAb sample collection.  The first SC injection should be administered by [CONTACT_541164] e supervision of the site’s investigator or designee.  Any issues may be reviewed at that time.  The firstinjection must be an abdominal injection.  Subsequently, 
the injection location may be the abdomen or upper front of either thigh.  The first T P4 injection at Week 22 and injections at Weeks 24, 26, 28 and 30 (before starting the PK 
profile )must also be administered in the abdomen under the supervision of the site’s investigator or designee.  Applicable injection details (eg, date) will be recorded in the 
electronic Participant Dosing Log.  Investigational product will be dispensed to the participant at each visit.
16. After [ADDRESS_705530] plus 2 weeks of PK profile participants are required to return for an end of treatment (EOT) visi t at Week [ADDRESS_705531] dose is scheduled, then will be followed up for final safety evaluation at Week 36, which may be a phone visit. Early terminated (ET) participants are 
required to return to the clinic as soon as possible after the last investigational product dose for an ET visit and safety phone follow up is also required at least [ADDRESS_705532] . Additional targeted PE may be performed at the ET and/or post-treatment follow up visits at the investigator’s discretion, as 
indicated by [CONTACT_168043]. 
17. The time investigational product period for actively eliciting and collecting AEs and SAEs (“active collection period”) for each participant begins from the t ime the
participant provides informed consent, through and including a minimum of [ADDRESS_705533]. Week 36 safety 
follow up may be conducted via phone. 
18. Concomitant medications will be routinely collected from the time the consent form is signed through the final study visit/contact.  If a participant discontinues early, 
concomitant medications must be followed for [ADDRESS_705534] .  Week 36 safety follow up m ay be conducted via phone. 
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 21Table 1. PK Sampling Table
Study 
PeriodTreatm ent 
Period 1Treatm ent 
Period 2Treatm ent 
Period 3Treatm ent Period 4
Visit ID Day 1 
Abd 
InjWk 
10
Abd 
InjWk 16
Abd InjWk 22
Abd InjWk 24
Abd 
InjWk 26 
Abd 
InjWk 
28 
Abd 
InjWk 
30 
Abd 
InjPK 
Day 
3PK 
Day 
4PK 
Day 
5PK 
Day 
7PK 
Day 
11Wk 
32
PK Profile 
Day1 3 4 5 7 11 15
Time (h) 
Post-Dose0a,b0a,b0a,b0a,b0a,b0a,b0a,b0a,b48 72 96 144 240 336a
PK 
Tolerance 
Window 
(h)d-48 -48 -48 -6 -6 -6 -6 -6c4c6c8c8c24c24c
a. Predose PK sample.
b. Injection on -site. 
c. PK sample must fall within the PK sampling time window for the participant to be Per Protocol (for the primary 
endpoint).
d. Blood samples for determination of adalimumab trough drug concentrations will be collected within [ADDRESS_705535] administration on Weeks 22, 24, 26, 28 , and on Day 1 (time 0), Weeks [ADDRESS_705536] administration
(ie,pre-dose) . The [ADDRESS_705537] (PK Profile Day 1): blood will be 
collected within [ADDRESS_705538]-Week 30 dosing times for serum collections are 48 (+ 4) hrs on PK Profile Day 3, 72 ( +6) hrs on PK Profile Day 4, 
96 (+8) hrs on PK Profile Day 5, 144 (+8) hrs on PK Profile Day 7, 240 (+ 24) hrs on PK Profile Day 11, and 336 (+24) 
hrs on PK Profile Day 15. Every effort should be made to draw samples within the specified time windows.  The 
2-week PK Profile collections may be completed using home health care service 
Abbreviations: Abd = abdominal; h = hour; Inj = injection; PK = pharmacokinetic; Wk = week .
2.INTRODUCTION
Adalimumab (marketed under the brand name [CONTACT_541192]®) is a recombinant fully  human 
Immunoglobulin G1 (IgG1)monoclonal antibody  (mAb) that specificall y binds to TNFα and 
blocks its interaction with the p55 and p75 cell surface TNF receptors, thereby  [CONTACT_541165].  HUMI RA is approved for use in both the 
[LOCATION_002] (US) and European Union (EU) for the treatment of rheumatoid arthritis ( RA), 
anky losing spondy litis (AS), psoriatic arthritis (PSA), polyarticular juvenile idiopathic 
arthritis, Crohn's disease (CD), pediatric CD, ulcerative colitis (UC), plaque psoriasis (PS), 
adult and adolescent hidradenitis suppurativa (HS), and pediatric and adult uveitis (UV); it is 
also approved in the EU for axial spondy loarthropathy  (radiographic -negative), pediatric 
plaque psoriasis, and juvenile enthesitis- related arthritis. 
PF-06410293 is a full y human IgG1 monoclonal antibody  (mAb) and has been approved by  
[CONTACT_4760] a biosimilar of adalimumab, also referred b y the brand name [CONTACT_541193].  The general term “adalimumab” is sometimes used for convenience when 
discussing the treatments in the 2 arms: switching and non -switching.  
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 222.1. S tudy Rationale 
The purpose of the trial is to support obtaining the FDA’s interchangeability designation, not 
to re-establish “PK equivalence” between licensed Humira and PF -06410293.  The objectives 
and design of this study  are generall y consistent with recommendations found in the 
corresponding FDA Interchangeability  guidance.[ADDRESS_705539], 
interchangeability  means that “the bi ological product may  be substituted for the reference 
product without the intervention of the health care provider who prescribed the reference 
product”.[ADDRESS_705540] to Humira.  
Biosimilarity  has been established through quality, nonclinical, and clinical assessments.  
Regulatory  approval forPF-06410293 as a biosim ilar to Humira was received from United 
States (US) Food and Drug Administration (FDA).  [COMPANY_007] seeks to demonstrate that 
PF-06410293 is interchangeable under Section 351(k)(4) of the PHS Act (FDA Guidance 
2015).8  A designation of interchangeability  means that ‘the risk in terms of safet y or 
diminished efficacy  of alternating or switching between use of the biological product and the 
reference product i s not greater than the risk of using the reference product without such 
alternation or switch’ (FDA Guidance, 2019).7
This I C study  has been designed to s upport the FDA interchangeability  designation. 
Humira is approved for use in both the [LOCATION_002] (US) (first licensed on 31 December 
2002) and European Union (EU) (first authorized on 8 September 2003).  
2.2.1. Clinical Overview
The clinical development prog ram for PF -06410293 consisted of 4 completed clinical 
studies: 3 single- dose PK studies (B5381001, B5381007, and B5381005) in healthy  subjects 
using a pre -filled s yringe (PFS) and a pre -filled pen (PFP) and 1 multidose safet y and 
efficacy  study  (B5381002) in patients with moderately  to severely  active RA using a PFS, 
which included a device substudy  using PFP.  This program demonstrated the clinical 
similarity  between PF -06410293 and Humira that supported the extrapolation to the Humira 
indications. 
The sa fety profile of PF -06410293 is consistent with that reported in the US Prescribing 
Information (USPI) and Summary  of Product characteristics (SmPC) of Humira.1,2  Data 
from the PF -06410293 clinical development program did not reveal an y new safet y risks for 
PF-06410293.  A summary  of the clinical safet y in the USPI  [INVESTIGATOR_541144]: 
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 23Serious Infections1
Increased risk for developi[INVESTIGATOR_511660]. 
Opportunistic infections due to bacterial, my cobacterial, invasive fungal, viral, 
parasitic, or other opportunistic pathogens have been reported with TNF blockers. 
Patients have frequently  presented with disseminated rather than localized disease.
Treatment should not be initiated in patients with an active infection, including 
localized infections . 
Patients greater than 65 years of age, patients with co -morbid conditions and/or 
patients taking concomitant immunosuppressants, may  be at greater risk of infection. 
Tuberculosis1
Reactivation of tuberculosis and new onset tuberculosis infections have been 
reported. 
Treatment of latent tuberculosis infection prior to therap y with TNF blocking agents 
has been shown to reduce the risk of tuberculosis reactivation during therapy . 
Consider anti -tuberculosis therap y prior to initiation of treatment. 
Invasive Fungal Infections1
Consider appropriate empi[INVESTIGATOR_129285] , taking into account both the risk for 
severe fungal infection and the risks of antifungal therap y.
Consider consultation with a phy sician wit h expertise in the diagnosis and treatment 
of invasive fungal infections. 
Hepatitis B Virus Reactivation1
Use of TNF blockers may  increase the risk of reactivation of hepatitis B virus .
Malignancies1
Non-Melanoma Skin Cancer (NMSC) : The rate (95% confidence interval) was 
0.8(0.52, 1.09) per 100 patient- years among HUMIRA -treated patients and 0.2 (0.10, 
0.59) per 100 patient- years among control- treated patients. 
Lym phoma and Leukemia: Th e observed rate of ly mphomas was approximately  
3-fold higher than expected in the general U.S. population according to the 
Surveillance, Epi[INVESTIGATOR_623] , and End Results ( SEER )database (adjusted for age, 
gender, and race).  Post-marketing cases of acute and chronic leukemia have been 
reported in association with TNF -blocker use in RA and other indications.  Even in 
the absence of TNF -blocker therapy , patients with RA may  be at a higher risk 
(approximately  2-fold) than the general population for the developmen t of leukemia. 
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 24Malignancies in Pediatric Patients and Young Adults: Malignancies, some fatal, have 
been reported among children, adolescents, and young adults who received treatment 
with TNF -blockers (initiation of therap y ≤18 y ears of age).  These cases were 
reported post -marketing and are derived from a variet y of source s including registries 
and spontaneous postmarketing reports. 
Hypersensitivity Reactions1
Anaph ylaxis and angioneurotic edema have been reported fo llowing HUMIRA 
administration. 
Allergic reactions (eg, allergic rash, anaph ylactoid reaction, fixed drug reaction, non -
specified drug reaction, urticaria) have been observed. 
Neurologic Reactions1
Rare cases of new onset or exacerbation of clinical sy mptoms and/or radiographic 
evidence of central nervous sy stem, and peripheral demy elinating disease. 
Hematological Reactions1
Rare reports of pancy topenia including aplastic anemia, medicall y significant 
cytopenia. 
Heart Failure1
Worsening congestive heart failure (CHF) and new onset CHF. 
Autoimmunity1
HUMI RAtreatment may result in the formation of autoantibodies. 
Development of a lupus -like sy ndrome.
2.3.Benefit/Risk Assessment
PF-06410293 has been approved by  [CONTACT_37368] a biosimilar to Humira . The clinical 
benefit of adalimumab (Humira®) is well establishe dand applies to both drugs used in this 
trial: PF-[ADDRESS_705541] common adverse reaction to 
adalimumab are injection site reactions, while the important identified risks include serious 
infections, malignancies, hy persensitivity  reactions, hematologic disorders, gastrointestinal 
disorders, heart failure and demy elinating disorders. 
PF-06410293 is approved by  [CONTACT_541166] (Humira®) USPI  [INVESTIGATOR_65073].  Appropriate risk evaluation and mitigation 
strategies have been incorporated into this protocol.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 25More detailed information about the known and expected benefits and risks and reasonabl y 
expected adverse events (AEs) of adalimumab may  be found in the Humira label, which is 
the SRSD for this study . 
3.OBJECTIVES, ESTIMAND S, AND ENDPOINTS
Objectives Estima nds Endpoints
Prim ary: Prim ary: Prim ary: 
To evaluate 
interchangeability of 
PF-06510293 and Humira by 
[CONTACT_541159] -state 
pharmacokinetics in a 
switching arm (following 
3switches betw een Humira 
and PF -06410293) as 
compared to a non-switching 
arm (receiving only Humira).Evaluate the equivalence of 
primary endpoints (maximum 
observed concentration (C max) 
and area under the 
concentration -time curve over 
the dosing interval (AUC ) 
obtained during the intensive 
PK sampling interval) between 
the switching arm and non -
switching arm in participants 
who meet the PK population 
criteria,that include criteria for 
the number and timing of 
missing doses, availability of 
PKdata, adherence to 
background therapy, and major 
protocol deviations re lated to 
PK assessment.Cmaxand AUC obtained 
during the intensive PK 
sampling interval. 
Objectives Estimands Endpoints
Secondary: Secondary: Secondary: 
To evaluate other serum 
adalimumab PK parameters 
in the switching arm andthe 
non-switching arm.
To evaluate the overall safety 
andtolerability of the 
switching arm and the 
non-switching arm.
To evaluate immunogenicity 
of the switching arm andthe 
non-switching arm .Summarize other serum 
adalimumab PK parameters , 
including time at which C max
occurs (T max), average 
concentration over the dosing 
interval (C av), and apparent 
clearance (CL/F) obtained 
during the intensive PK 
sampling interval in participants 
who meet the PK population 
criteria, and predose 
concentration during multiple 
dosing (C trough)obtained at 
scheduled PK sample 
timepoints in participants who 
meet the safety population 
criteria, for the switching arm 
and non -switching arm.Other serum adalimumab PK 
parameters, including T max, 
Cav, and CL/F obtained 
during the intensive PK 
sampling interval and Ctrough
obtained at scheduled PK 
sample tim epoints .
Safety measures 
characterized by [CONTACT_24975], 
incidence, severity, timing, 
seriousness and relatedness 
of treatment -emergent 
adverse events (AEs) and 
laboratory test abnormalities .
Percent of participants with 
ADA/NAb and ADA/NAb 
titers over time.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 26Summarize safety endpoints for 
the switching arm and 
non-switching arm in 
participants who meet the safety 
population criteria.
Summarize percent of 
participants with antidrug 
antibodies (ADA), and 
neutralizing antibodies (NAb) 
and ADA/NAb titers over time 
for the switching arm and 
non-switching arm in 
participants who meet the 
Safety population criteria .
4.STUDY DESIGN
4.1.Overall Design
This is an open -label, multi- national, 2 -arm, randomized, parallel -group study  designed to 
evaluate the interchangeability  of the switching arm ( PF-06410293 and Humira ), compared 
to non-switching arm ( Humira ), in participants with moderatel y to severel y active RA on 
background methotrexate (MTX).  For purposes of this protocol, the treatment arm that 
includes switches between PF -06410293 and Humira will be referred to as the “switching” 
arm, while the treatment arm that comprises continuous Humira treatment will be referred to 
as the “non- switching” arm.
This stud y will enroll a maximum of approximately [ADDRESS_705542] 10 weeks, all 
participants will receive Humira [Treatment Period (TP) 1].  Upon completion of TP1, 
participants will be randomized (1:1 ratio) into either the switching or the non -switching arm
prior to dosing on Week 10.  Randomization will be stratified b y 3 bod y weight groups 
(Week 10 weight) ( ≥40 kg to <70 kg;  70 kg to <100 kg; 100 kg to ≤ 130 kg).  Participants 
randomized to the non- switching arm will continue on Humira for the remainder of the stud y, 
and participants randomized to the switching arm will continue switching in each TP (TP2: 
PF-[ZIP_CODE] 293; TP3: Humira; TP4: PF -06410293).
TP1 (Lead In Period) will begin with the first dose of investigational product on 
Week 0 (Day  1) and conclude with the completion of Week 10 pre-dose assessments. 
TP2 will begin with the 1:[ADDRESS_705543] dosing for 
Week 10 will begin after the randomization process in the respective treatment arms 
and will conclude with the completion of Week 16 pre-dose assessments.  
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 27TP3 will begin with investigational product dosing on Week 16, and conclude with 
the completion of Week 22 pre-dose assessments.  
TP4 will begin with investigational product dosing on Week [ADDRESS_705544] dosing is scheduled at Weeks 22, 24, 
26, 28, and 30, followed by  a 2-week PK sampling period from Week 30 to Week 32. 
TP4 will conclude with end of treatment (EoT) assessments and final dose 
administration at Week 32.  
The 2 -week PK sampling period starts with Week 30 predose PK collection and 
ends with predose PK collection on Week 32. 
Safety  Follow -Up Period begins after the last investigational product dosing on 
Week 32, and concludes at completion of the Week 36 assessments.  All participants 
(including earl y discontinuations) will be followed for at least [ADDRESS_705545] bioequivalence (BE) approach with acceptance margins of 80.00% to 125.00%.  
Specific details regarding statistical approaches to data anal ysis for this study  are discussed 
further in Section 9.
This study  is also designed to evaluate safet y and immunogenicit y after several 
investigational product switches between the switching and non- switching arms .
4.3.Justification for Dose
The [ADDRESS_705546] ADA formation 
and PK, as well as safet y (see Section 6.6).
4.4.End of Study Definition
A participant is considered to have completed the study  if he/she has completed all treatment 
periods of the stud y, includin g the EoT visit (Week 32).  The final safet y follow -up is at 
Week 36, which may be done by  [CONTACT_648].  Early  discontinuation from investigational product
requires participants to return as soon as possible after the last dose of investigational product
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 28for an EoT visit.  A safety  follow -up (may  be done by  [CONTACT_648]) at least [ADDRESS_705547] y:
Age and Sex:
1.Male or female participants between the ages of 18 (or the minimum country -specific 
age of consent if >18) and 70 y ears, inclusive, at Visit 1 (Screen 1).
Refer to Appendix 4 for reproductive criteria for male ( Section 10.4.1 ) and female 
(Section 10.4.2 ) participants.
Type of Participant and Disease Characteristics:
2.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, lifesty le conside rations, and other study  procedures.
3. Diagnosis of rheumatoid arthritis (RA) based on 2010 American College of 
Rheumatology  (ACR)/European League Against Rheumatism (EUL AR) 
classification criteria for RA for at least a [ADDRESS_705548] received oral, subcutaneous (SC), or IM methotrexate for at least [ADDRESS_705549] of care. 
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 296.Stable dose of oral folic acid (at least 1 mg/day  on 5days per week) or oral foli nic 
acid (≥5mg once per week) supplementation for at least [ADDRESS_705550] approved 
folic acid 1 mg or folinic acid 5 mg presentations, a regimen of folic acid of 5mg 
weekl y is acceptable. 
Weight:
7.Body mass index (BMI) of 18 to 45 kg/m2and a total body  weight of ≥40 kg 
(88pounds) to ≤130 kg (287 pounds). 
Informed Consent:
8.Capable of giving signed informed consent as described in Appendix 1 , which 
includes compliance with the requirements and restrictions listed in the informed 
consent document (ICD) and in this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Con ditions:
1.Evidence or history  of nervous sy stem dem yelinating diseases (including multiple 
sclerosis, optic neuritis, Guillain- Barré s yndrome).  
2.History  of seizure disorder requiring treatment in the previous 5 years prior to 
Screening.
3.History  of or activ e significant infection defined by :
a.History  of recurrent (more than one epi[INVESTIGATOR_1865]) limited herpes simplex which 
requires current chronic antiviral therap y, or disseminated (a single epi[INVESTIGATOR_1865]) 
herpes simplex. 
b.History  of disseminated or recurrent infection with Epstein Barr virus (EBV), 
human papi[INVESTIGATOR_27509] (HPV), or varicella zoster.  A single, limited epi[INVESTIGATOR_541145] . 
c.Any infection requiring hospi[INVESTIGATOR_541146] b y the investigator within [ADDRESS_705551].
d.History  of an infected joint prosthesis at any  time, with the prosthesis still in situ.
e.SARS -CoV2 infection (COVID -19) should be considered clinicall y significant , 
local guidelines on COVID -[ADDRESS_705552] confi rmed positive for human immunodeficiency  virus (HIV), 
hepatitis B virus, or hepatitis C (HCV) virus (please see Section 8.2.8 for details on 
testing). 
a.Positive for HIV.
b. P ositive hepatitis B surface antigen (HBsAg) .
c.Positive hepatitis B core antibody  (HBcAb) without positive hepatitis B surface 
antibody  (HBsAb) (unless it is documented that hepatitis B DNA test is negative).
d. P ositive hepatitis C antibody  (HCV Ab) results and positive confirmat ory HCV 
riboneucleic acid (HCV RNA) results.
5.Evidence of current or recent history  of uncontrolled, clinically  significant 
hematological, renal, endocrine, pulmonary , gastrointestinal, hepatic, infectious, 
psychiatric, neurologic, allergic, or cardiovascul ar disease including evidence or 
history  of moderate or severe heart failure (NYHA Class III/IV) or Screening 12 -lead 
electrocardiogram ( ECG )that demonstrates clinically  relevant abnormalities which 
may affect participant safety , and participants who are contraindicated for treatment 
with adalimumab in accordance with the approved local label.
6.History  of any  lymphoproliferative disorder (eg, EBV related l ymphoproliferative 
disorder, l ymphoma, or leukemia).  Evidence or history  of a malignancy  within the 
past 5years (with the exception of adequately  treated or excised non -metastatic basal 
cell or squamous cell cancer of the skin, or cervical carcinoma in situ with no 
evidence of recurrence). 
7.History  of recurrent inflammatory  joint disease other than RA (eg , post infectious 
arthritis, gout, etc.) or history  of any  other autoimmune rheumatic diseases 
(eg,vasculopathies, spondy loarthropathies, etc.) other than Sjogren’s s yndrome.
8.Significant trauma or surgical procedure within [ADDRESS_705553] .
10.Other acute or chronic medical or ps ychiatric condition including recent (within the 
past y ear) or active suicidal ideation or behavior or laboratory  abnormality  that may  
increase the risk associated with study  participation or investigational product 
administration or may  interfere with the interpretation of study  results and, in the 
judgment of the investigator, would make the participant inappropriate for entry  into 
this study .
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 31Prior/Concomitant Therapy:
11. Prior/Current treatment with adalimumab. 
12.More than 3 disease modify ing anti- rheumatic drug s (DMARD s)in combination 
therap y; concomitant DMARD therap yincluding small molecules, biologic s,and 
biosimilars, with the except ion of methotrexate (as specified in Section [IP_ADDRESS] )and
stable dose ( at least 4 weeks) of leflunomide, anti-malarials and sulfasalazine (please 
refere nce Section 6.5and Appendix 9 ).  
13. P rior ly mphocy te depleting therapi[INVESTIGATOR_014] (eg, rituximab, Campath) with remaining 
lymphocy te depletion.
14. Known requirement for treatment with prohibited concomitant medications during the 
study .
15.Exposure to any  live vaccines within [ADDRESS_705554] .
16.Intra - articular (IA) corticosteroids administered within 4 weeks prior to Screening.
17.Unstable dose (less than 4 weeks ) of oral and IM corticosteroid prior to first study  
dose.
Prior/Concurrent Clinical Study Exper ience:
18.Previous administration with an investigational drug within 30 days (or as determined 
by [CONTACT_19970]) or within [ADDRESS_705555] used in this study  (whichever is longer) is not permitted. 
Diagnostic Assessments:
19.Clinically  significant laboratory  abnormalities at Screening, including but not limited 
to inadequate bone marrow, liver, renal and immune sy stem function as defined by  
[CONTACT_541167]:
a.Hemoglobin (Hgb) <9 g/dL.
b. Absolute neutrophil count (ANC) 1500 cells/mm3.
c.White blood cell (WBC) count <3.0 x 109/L.
d.Lym phocy te count of <0.5 x 109/L
e.Platelets <100 x 109/L.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 32f.Aspartate aminotransferase/alanine aminotransferase (AST/ALT) 2times the 
upper limit of normal.
g.Total bilirubin 1.5times the upper limit of normal.
h.Serum creatinine 1.5mg/dL.
i.Serum albumin <3.0 g/dL.
20.Evidence of untreated or inadequatel y treated latent or active tuberculosis (TB) 
infection as defined below (See Section s 6.5and Section 8.2.6 ): 
a.If screening QuantiFERON -TB test is positive or indeterminate in a participant 
without history  of active or latent TB, a retest of QuantiFERON -TB is required 
and the participant should be referred to a specialist according to local practice
(eg, pulmonologist, TB specialist or infectious disease specialist) for further 
evaluation of latent or active TB or false positive QuantiFERON- TB test result.  
Participants who are determined to have a false positive QuantiFERON -TB test 
result by  [CONTACT_541168]. 
b. Participants diagnosed with latent TB at Screening are required to receive at least 
4weeks of chemproph ylaxis according to local clinical guidelines and repeat 
aminotra nsferases (ALT/AST) within at least [ADDRESS_705556] completed a 
successful course of chemoprophy laxis in accordance with local guidelines; or if 
chemoproph ylaxis is still ongoing, participants must have received at least 
4weeks before receiving study  dose on Day  1.  Participants need to commit to 
completion of the chemoprophy laxis course. 
21.Chest radiograph y (or alternative chest imaging, ie ,chest co mputed tomography  (CT)
scan) with evidence of active TB, fungal infections, or other clinicall y significant 
abnormalities taken within [ADDRESS_705557] imaging result 
consistent with prior TB (active or latent) will not exclude the participant.  (See 
Section 8.2.3 ) 
22. Positive urine drug test at Screening for substances of abuse that is not due to 
prescribed medication, or past or current history  of addiction to or dependence on 
non-prescribed substances within 12 months prior to Screening.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 33Other Exclusions:
23.Investigator site staff members directl y involved in the conduct of the study and their 
family  members, site staff members otherwise supervised by  [CONTACT_093], o r 
[COMPANY_007] employ ees, including their family  members, directly  involved in the conduct of 
the study . 
24.Pregnant females and breastfeeding females, male participants with partners currentl y 
pregnant who are unwilling to use a condom, or male and female participants of 
childbearing potential who are unwilling or unable to use an effective method of 
contraception as outlined in this protocol for the duration of the study and for at least 
5months after the last dose of investigational product . 
5.3.Lifestyle C onsiderations
No lifesty le restrictions are required.  
5.3.1. Contraception 
The investigator or his or her designee, in consultation with the participant, will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and his or her partner(s) from the permitted list of contrac eption methods (see 
Appendix 4 and Section 10.4.4 ) and will confirm that the participant has been instructed in 
its consistent and correct use.  At time points indicated in the SoA, the investigator or 
designee will inform the participant of the need to use effective contraception consistently  
and correctly and document the conversation and the participant’s affirmation in the 
participant’s chart (participants need to affirm their consistent and correct use of at least 1 of 
the selected methods of contraception).  In addition, the investigator or designee will instruct 
the participant to call immediately  if the selected contraception method is discontinued or if 
pregnancy  is known or suspected in the participant or partner.
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  enrolled to receive investigational product .  A minimal set of screen 
failure information is required to ensure transparent reporting of s creen failure participants to 
meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements 
and to respond to queries from regulatory  authorities.  Minimal information includes 
demograph y, screen failure details, eligibility  criteri a, and an y SAE.
Participants who do not meet all eligibility  criteria may  be retested (under the same screening 
number) within the [ADDRESS_705558] result(s) meet the eligibility  
criteria, the participant will not be considered as a screen fail and may  enroll into the study .  
Individuals who do not meet the criteria for participation in this study  within the [ADDRESS_705559]
Study  interv ention is defined as an y investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study  participant according to 
the study  protocol.
For the purposes of this protocol, the term investigational pro duct may  be used 
synony mously  with investigational product .
6.1.Investigational Product (s) Administered
The following table outlines the two investigational products used in this protocol. For more 
detailed information please refer to the Investigational Prod uct (IP) Manual.
Intervention Name [INVESTIGATOR_16335]-06410293 Humira
Type Biologic Biologic
Dose Form ulation solution for injections/solution for 
injectionsolution for injections/solution 
for injection 
Unit Dose Strength(s) 40 mg /0.8 mL 40 mg/ 0.4 mL
Dosage Level(s) 40 mg every 2 weeks 40 mg every 2 weeks
Route of Adm inistration Subcutaneous (SC) Subcutaneous (SC)
Investigational Medicinal 
Product (IMP) and 
Noninvestigational 
Medicinal Product (NIMP)IMP IMP 
Sourcing Provided centrally by [CONTACT_541169]. Each carton will contain 
one syringe and will be labeled as 
required per country requirement.Investigational product will be 
provided in an Open Labeled 
Carton.  Each carton will contain 
one syringe and will be labeled 
as required per country 
requirement.
6.1.1. Administration
Investigational product will be administered by  [CONTACT_2299], care giver or site personnel
every  other week using pre -filled syringes provided by [CONTACT_456] .  All participants will 
receive instruction on administration of investigational product by [CONTACT_541170] (IFU) (see Section 6.1.2 ).  Participants who are not 
capable of, or choose not to administer investigational product, may  have their injections 
administered b y a care -giver following the IFU.  Onsite injections will occur at every  
scheduled visit, after the PK and ADA/NAb sample is collected (See SoA and Table 1.PK 
Sampling Table ).
The first SC injection should be administered at the site under the supervision of the site’s 
investigator or designee, and the participant will be assessed for their ability  to inject 
adalimumab. Any issues may be reviewed at that time. The firstinjection must be an 
abdominal injection.  The first TP4 injection at Week 22 and injections at Weeks 24, 26, 28 
and 30 (before starting the PK profile) must also be administered in the abdomen under the 
supervision of the site’s investigator or designee.  All other injections may  be administered in 
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 35the abdomen or upper front of either thigh .  Applicable injection details (eg, date) will be 
recorded in the electronic Participant Dosing Log.  I nvestigationa l product will be dispensed 
to the participant at each visit.
Following the first injection at the site, the participant should select a day  of the week for 
their every  other week injections at home. For example, if the first injection occurred on a 
Monda y (study  Day 1) the participant should continue every other week injections on a 
Monday  (study  Day 15). Participants should select a day  of the week which will most likely  
ensure compliance (eg, no late or forgotten doses). On-site injections will occur under the 
supervision of the site’s investigator or designee during the scheduled visits (See SoA). Any 
participant found to be non- compliant for an y reason other than safety should be instructed to 
administer the non -compliant dose as soon as he/she remembers, as long as the time elapsed 
following the intended dosing time is ≤7 day s. He/she should inject the next dose as 
scheduled. Once 7 day s passes from a regularly  scheduled dose, the delayed dose in the 
previous 2 week dosing period will be considered missing (not delay ed), and shall not be 
administered. It is critical for participants be compliant with the dosing schedule. In 
particular, participant dosing compliance during TP4 is critical in order to achieve the 
primary  objective of this study .In order to support PK collection starting at Week 30, 
participants must have received (at a minimum) [ADDRESS_705560] be admini stered in the abdomen while at the 
clinic under the supervision of the site’s investigator or designee.  
Applicable a dalimumab injection details (eg, dates) will be recorded in the electronic 
Participant Dosing Log by [CONTACT_2299].  Once the pre -filled sy ringe is used the empt y 
investigational product container should be returned .  The drug will be injected into a 
quadrant of the abdominal wall, remaining 2” inches/[ADDRESS_705561].  
Participants should call the study  site to discuss any  problems, issues, and concerns related to 
the drug administration.  Participants should return any  dropped (while uncapped) or frozen 
unused sy ringes.  If a potential defect is noted in the prefilled s yringe (or its labeling or 
packaging), or the s yringe fails to perform, the s yringe should be returned to the site and the 
site should file a Medical Device Complaint (Refer to the IP Manual for specific instructions 
related to the form).  Site staff should also follow the above described process to inspect the 
pre-filled s yringe for onsite injections and rep ort issues as noted. 
Participants will be instructed to dispose of their used needles and s yringes in a FDA -cleared 
biohazard disposal container immediatel y after use. Participants must not dispose their used 
biohazard disposal container in their househo ld trash but may  return them to the site, or they  
may dispose of them locally  according to local guidelines. 
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 36Reference the IP manual for further details.
6.1.2. Training for Adalimumab Subcutaneous Injections
All participants will be provided the Instruction For Use (IFU) and will be supervised for the 
administration of their first dose of investigati onal product on study  Day 1.  As noted above, 
the first SC injection must be an abdominal injection.  The first TP4 injection at Week 22 and 
injections at Weeks 24, 26, 28 and 30 (before starting the PK profile) must also be 
administered in the abdomen under the supervision of the site’s investigator or designee
(please also refer to Section 6.1).All other injections may  be administered in the abdomen or 
upper front of either thigh.   IFU of the investigational product will be provided to the 
participant on Day [ADDRESS_705562] .  
6.1.3. Medical Devices 
1.The [COMPANY_007] manufactured medical device (or device manufactured for [COMPANY_007] by  a third 
party ) provided for use in this study  is the PF- 06410293 solution for injection 
prefilled syringe.
2.Other medical device (not manufactured by  [CONTACT_541171]) provided for use in this 
study  is the Humira solution for injection sy ringe. 
3.Instructions for medical device use are provided in the I nstruction For Use.
4.Medical device incidents must be detected, documented, and reported b y the 
investigator throughout the study  (see Section 8.3.7 ).  For device incidents resulting 
from malfunction s of the device please also refer to the I nvestigational Product 
Manual for the de vice complaint process instructions.
6.2.Preparation/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been mainta ined during transit for all investigational product received and that any  
discrepancies are reported and resolved before use of the investigational product , as 
applicable for temperature -monitored shipments. 
2.Only  participants enrolled in the study  may  receive investigational product and only
authorized site staff may  supply  or administer investigational product.  All 
investigational products must be stored in a secure, environmentall y controlled, and 
monitored (manual or automated recording) area in accordance with the labeled 
storage conditions with access limited to the investigator and authorized site staff.  At 
a minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request.  Data for nonworking days must 
indicate the minimum and maximum temperature since previousl y documented for all 
site storage locations upon return to business.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 373.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible fo r investigational product accountability , reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records).  All 
investigational products will be accounted for using an investigational product 
accountability  form/record. Once the pre -filled s yringe is used, the empt y 
investigational product container should be returned .  
4. Further guidance and information for the final disposition of unused investigational 
product s are provided in the I P manual.
5.Any storage conditions stat ed in the SRSD will be superseded b y the storage 
conditions stated on the product label. 
6.Investigational product s should be stored in their original containers and in 
accordance with the labels. 
7. Site staff will instruct participants on the proper storage requirements for take -home 
investigational product. 
8.Any excursions from the investigational product label storage conditions should be 
reported to [COMPANY_007] upon discovery  along with an y actions taken.  The site should 
activel y pursue options for returning the investigational product to the storage 
conditions described in the labeling, as soon as possible.  Once an excursion is 
identified, the investigational product must be quarantined and not used until [COMPANY_007] 
provides permission to use the investigational product .  It will not be considered a 
protocol deviation if [COMPANY_007] approves the use of the investigational product after the 
temperature excursion. Use of the investigational product prior to [COMPANY_007] approval 
will be considered a protocol deviation. Speci fic details regarding the definition of an 
excursion and information the site should report for each excursion will be provided 
to the site in the I P manual.
9. The sponsor or designee will provide guidance on the destruction of unused 
investigational product (eg, at the site).  If destruction is authorized to take place at 
the investigator site, the investigator must ensure that the materials are destroy ed in 
compliance with applicable environmental regulations, institutional policy , and any  
special instruct ions provided by [CONTACT_4618], and all destruction must be adequately  
documented.
Additional details about accountability , storage, destruction, and excursion reporting can be 
found in the I P manual.
PF-[ADDRESS_705563] prior to use.
Single use PF -06410293 and Humira will be provided to the participants in pre -filled s yringe 
(PFS) which are individually  packaged in containers with tamper evident seals.  The cartons 
should not be opened until the drug is to be administered.  The investigational product will be 
dispensed using an interactive response technology  (IRT) drug management sy stem at each 
visit from Week 0 to Week 32; investigational product will be given to the par ticipants for 
the exact number of doses needed between visits from Week [ADDRESS_705564] at the site, it is important that the study personnel 
handle only  oneparticipant’s investigational product container(s) at a time, to avoid a mix up 
with another participant’s investigational product container(s).
If applicable, please reference Appendix [ADDRESS_705565] 
dispensing during the COVID -19pandemic .
6.3.Measures to Minimize Bias: Randomization and Blinding
This is an open -label study .  
Upon successful completion of TP1, participants will be randomized (1:1 ratio) into either 
the switching arm (ie, to PF -06410293) or the non -switching arm (ie, continue to receive 
Humira).  Randomization will be stratified by  3 bod yweight groups ( 40kg to <70 kg; 
70kg to <100 kg;  100 kg to ≤130 kg).  Participants randomized to the Humira arm will 
continue on Humira for the remainder of the stud y, and participants randomized to switch to 
PF-06410293 will continue switching in each TP (TP2: PF -06410293; TP3: Humira; TP4: 
PF-06410293).
6.3.1. Allocation to Investigational Product
Allocation of participants to treatment groups will proceed through the use of an interactive 
response technology  (IRT) sy stem (interactive Web -based response [I WR]).  The site 
personnel (stud y coordinator or specified d esignee) will be required to enter or select 
information including but not limited to the user’s identification (ID) and password, the 
protocol number, and the participant number.  
This is an open -label study ; however, the specific investigational product dispensed to the 
participant will be assigned using an IRT. The site will contact [CONTACT_541172] 1, if the participant is found to be eligible for the 
study .  On Study  Day  [ADDRESS_705566] administration for each participant to randomize the 
participant into the study  (see Section 6.3). The site will record the investigational product 
assignment on the applicable case report form. Potential bias w ill be reduced b y central 
randomization.
The investigator’s knowledge of the treatment should not influence the decision to enroll a 
particular participant or affect the order in which participants are enrolled.
Investigational product will be dispensed at the study  visits summarized in the SoA. 
The study -specific I RT reference manual and I P manual will provide the contact [CONTACT_19974] s ystem.
6.3.2. Breaking the Blind (Not Applicable)
This is an open -label trial. 
6.4.Investigational Product Compliance
Participant compliance will be verified b y the review of the electronic Participant Dosing 
Log (or relevant source document ),the returned unused investigational product, and 
accounting for a ny unused investigational product by [CONTACT_2299]. When investigational 
product is administered at the study  center (eg, Day  1dosing), it will be administered under 
the supervision of study  personnel (see Section 6.1). Compliance will be evaluated at all 
study  visits beginning at Week 4. Participants will be directed to record the applicable 
injection details (eg, date) in the electr onic Participant Dosing Log, and site personnel will 
enter this information onto electronic case report form (eCRF) . Any participant found to be 
non-compliant for a reason other than safety should be instructed to self -administer the 
missed dose as soon as possible, as long as the time elapsed following the intended dosing 
time is ≤7 day s. He/she should inject the next dose as scheduled. Once 7 day s passes from a 
regularl y scheduled dose, the delayed dose in the previous 2 week dosing period will be 
considered missing (not delay ed), and shall not be administered. The participant should be 
reeducated on the every  other week dosing regimen, and to revert to the original calendar day  
scheduled after an y single dose outside the original calendar schedu le. The investigator or 
designee should assess potential factors leading to less than complete compliance and take 
steps to improve compliance (see Section 7.1.1 ). Compliance and non -compliance of study  
participants will be monitored by  [CONTACT_541173]. See Section 7.1for 
discontinuation of participants with noncompliance.
If applicable, please reference Appendix 11for alternative options on investigational product 
compliance during the COVID -19 pandemic.
6.5.Concomitant Therapy
Hormonal contraceptives that meet the requirements of this study  are allowed to be used in 
participants who are WOCBP (see Appendix 4 ).
PF-[ADDRESS_705567] therap y (with the exception of methotrexate as 
specified in Section [IP_ADDRESS] ) and stable dose (at least 4 weeks) of leflunomide, anti -malarials 
and sulfasalazine the doses can be reduced or discontinued as per medical judgement .  In the 
case of suspected COVID -[ADDRESS_705568] therap y during the stud y is prohibi ted.  A combination of no more than 
3DMARDs is permitted during the stud y.
Participants are encouraged to bring their vaccinations up to date prior to initiating 
adalimumab; any live attenuated vaccine must have been administered at least [ADDRESS_705569] 
radiograph y (or alternative chest imaging) and QuantiFERON-TB Gold In -Tube Test 
results indicate no evidence of TB infection, but who are considered b y the investigator to be 
at high risk to develop tuberculosis (eg, residing in high -risk areas or travel to high -risk 
areas), may  be started on a course of TB prophy laxis or treatment in ac cordance with local 
guidelines at the discretion of the investigator.  If TB proph ylaxis treatment is started after 
the Screening visit, aminotransferases (ALT/AST) levels should be checked within at least 
4weeks prior to first investigational product in TP1 to confirm results fulfill entry  criteria.
It is recommended that participants avoid changing prescription or non -prescription drugs, 
vitamins, and dietary  supplements within 7 days or 5 half-lives (whichever is longer) prior to 
the first dose of investigational product and prior to study  visits unless otherwise noted 
below, throughout the study . 
Concomitant medications will be collected at each visit/contact [CONTACT_541174]/contact.  All concomita nt medication taken during the 
study  (prescription, non- prescription drugs, and non -drug therap y as appropriate) must be 
recorded on the eCRF with daily  dose, and start and stop dates of administration.  If a 
participant discontinues early , concomitant medications must be followed at the EoT visit, 
the safet y follow- up visit at least [ADDRESS_705570] and/or extended safety  follow -up.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 41Concomitant medications prohi bited in the study  are summarized in Appendix 10 .
6.5.1. Stable Background Therapi[INVESTIGATOR_014]
[IP_ADDRESS]. Methotrexate
Adalimumab must be administered concomitantly with a stable dose of MTX throughout the 
course of stud y treatment. 
The administration o f MTX, including dosage, laboratory testing, follow -up care (including 
contraception requirements), and contraindications should be performed according to local 
standards of care throughout the study . 
At study  entry , participants must have received oral o r IMMTX for at least [ADDRESS_705571] be 
documented with the investigator’s medical justification.  Participants will not be 
discontinued from study  treatment following a justified dose reduction of MTX, unless the 
MTX is adjusted below the minimal required dosage level of 7.5 mg/week (or a dose as low 
as 6mg/week in geographic regions where permitted by  [CONTACT_541175] ). 
[IP_ADDRESS]. Folic/Folinic Acid Supplements
Participants are required to receive a stable background dose of oral folic/folinic acid 
supplementation throughout the st udy.  Participants must have received an adequate stable 
dose of oral folate (at least 1 mg/day  on  5days per week) or oral folinic acid ( 5mg once 
per week) for at least [ADDRESS_705572] 5mg 
weekl y is acceptable.  
[IP_ADDRESS]. Additional Background Therapi[INVESTIGATOR_541147], including corticosteroids, a 
NSAID or Cycloox ygenase -2 (COX -2)inhibitor, and non -opi[INVESTIGATOR_541148]/narcotic 
analgesics (see Section 6.5.2 , Section 6.5.3 and Appendix 9 ).  
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 426.5.2. Pain or Other Arthritis Therapy
Participants may receive the following concomitant medications during the study  under 
restricted conditions as specified below:
1.Participants may be taking one NSAID, including a COX -2inhibitor.  At the 
discre tion of the investigator, the dosage may  be adjusted to protect a participant’s 
safet y during the stud y.  
2.Participants may  additionally  be receiving low dose aspi[INVESTIGATOR_541149] 
(325mg per day ).
3. Intra articular (IA) corticosteroids, oral and IM corticosteroids are allowed as rescue 
therap y, as described in Section 6.5.[ADDRESS_705573] study  treatment dose.  At the discretion of the investigator, the corticosteroid 
dosage may  be adjusted during the t rial as per investigator’s medical judgment.  
Tapering or discontinuation of the corticosteroid treatment should be performed as 
per local standard of care .
4.Participants receiving regular daily  doses of onl y one of the allowed 
immediate -release opi[INVESTIGATOR_2438]/nar cotics (including tramadol) as listed in Table 2, and/or a 
regular a dail y dose of up to 2 grams/day  (or maximal local label dail y dosage) of 
acetaminophen or 3 grams/day  of paracetamol (eg, not using analgesic medication ‘as 
needed’) according to local guidance, must be on stable doses for at least 2 weeks 
prior to Day 1.  Less frequent dosing or cessation of analgesic therap y should be 
performed as pe r investigator’s medical judgment. 
5.New or increased doses of following medications will be allowed as rescue therap y, 
as described in Section 6.5.3 . 
Table 2.Permitted Opi[INVESTIGATOR_2480]/Narcotic Drugs
Drug Example Trade Names Maximum Allowed Total Daily 
Dose
Tramadol Ultram, Zydol, Zamadol, 
Ultracet, Tramal300mg
Codeine Tylenol #2 and #3, Paveral 200mg
Hydrocodone Vicodin, Lortab 30 mg
Oxycodone Roxicodone, Percocet, 
Tylox (not: OxyContin®)15mg
Propoxyphene HCl or 
Propoxyphene napsylateDarvon, Darvocet, 
Doloxene, Darvon- N, 
Darvocet -N 100300mg propoxyphene HCl
400mg propoxyphene napsylate
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 436.5.3. Rescue Medicine 
1.Analgesics: New or increased acetaminophen/paracetamol, current tramadol or other 
single opi[INVESTIGATOR_2480]/narcotic drug (see Table 2), or another allowed opi[INVESTIGATOR_2480] (see Ta ble3)are
allowed as rescue medications according to the local label.  
Table3.Additional Opi[INVESTIGATOR_541150]  
(not: MS Contin®)30 mg
Hydromorphone Dilaudid 7.5 mg
Meperidine Demerol, Pethidine 300 mg
For participants who are receiving regular daily  doses of one of the allowed 
opi[INVESTIGATOR_2438]/narcotics:
If the opi[INVESTIGATOR_2480]/ narcotic is tramadol, hy drocodone, or oxy codone, the dosage may  be 
increased up to the maximum total daily  dosage limits for rescue purposes.  
However, participants can NOT add a second opi[INVESTIGATOR_2480]/ narcotic agent for rescue; 
therefore, an y original opi[INVESTIGATOR_541151] a new opi[INVESTIGATOR_2480]/narcotic is 
started for rescue. 
For participants who are not on a regular daily  opi[INVESTIGATOR_2480]/narcotic therapy :
Sustained release morphine formulations (eg, MS Contin®), susta ined release 
oxycodone formulations (eg, Oxy Contin®), and propoxy phene HCL/naps ylate are 
not allowed for rescue medication.
2.IA corticosteroids may  not be administered within 4 weeks prior to Screening visit.  
However, IA injections of corticosteroids are a llowed as rescue therap y in this study  
in accordance with the local label.
The following restrictions will apply  when the rescue injections are performed:
Rescue injections should be performed following the joint assessment after 
Screening visit.
Investiga tors should follow local standard of care where participants should 
receive no more than one injection per month and no more than three injections 
per year.
Arthrocentesis without injection of an y IA medication is allowed. The joint 
having arthrocentesis will be considered as having its pre -injection status for the 
joint counts.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 443.Non-pharmacologic treatment, including application of heat and cold, massage, 
physical therap y, splinting, or ultrasound is allowed.
6.6.Dose Modification 
No dose adjustment (dosage or dosing frequency ) will be allowed in the study . 
6.7.Intervention After the End of the Study
No intervention will be provided to study  participants after the end of the study .
7.DISCONTINUATION OF INVESTIGATIONAL PRODUCT AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1.Discontinuation of Investigational product
In rare instances, it may  be necessary  for a participant to permanentl y discontinue 
investigational product prior to completing the study .If investigational product is 
permanentl y discontinued, the participant will remain in the study  to be evaluated for at least 
[ADDRESS_705574] for monitoring of AEs/SAEs and 
concomitant medications. 
Reasons for discontinuation from study  treatment may  include, but will n ot be limited to:
AE potentially  attributable to investigational product that in the opi[INVESTIGATOR_541152] y, including but not limited to severe 
hypersensitivity  reactions, serious infections (see Section 2.3Benefit/Risk 
Assessment), active/latent tuberculosis, serious cardiac arrh ythmias, or new or 
worsening congestive heart failure. 
Inadequate response to study  treatment, in the judgment of the investigator (per local 
standard of care and/or guideline s).
Participant noncompliance.
Participant choice to withdraw from treatment (follow -up permitted by  [CONTACT_3445]).
Participant choice to withdraw from study  participation (cessation of follow -up).
Participant lost to follow -up.
Participant pregnancy .
Note that discontinuation of investigational product does not represent withdrawal from the 
study .
See the SoA for data to be collected at the time of intervention discontinuation and follow -up 
and for an y further evaluations that need to be c ompleted.
PF-[ADDRESS_705575] 
2doses of TP4.  Temporary  treatment discontinuation should also be considered in the case 
of a known SARS -CoV 2exposure or suspected COVID -19 infection until full clinical 
assessment is completed.
Participants who experience a serious infectious AE (e g,life-threatening, requiring 
hospi[INVESTIGATOR_11298] , documente d COVID -19infection , etc.) or sepsis should be permanentl y 
discontinued from study  treatment.   
Delay ed treatment due to other non-medical reasons (eg, participant is out of town and 
forgets to take their investigational product containe r) should be prevented as much as 
possible by  [CONTACT_541176]’s plans and educating him/her about the regular every  
other week dosing schedule. In TPs 1 –[ADDRESS_705576] 2 doses in TP4, a participant who 
misses a dose should be instructed to t ake the missed dose as soon as he/she remembers, as 
long as the time elapsed following the intended dosing time is <7 day s. He/she should take 
the next dose as scheduled. To be included in the PK analy sis, it is critical for participants to 
not miss (see Section 9.3):
The last 3 doses in TP4;
The first dose of the study in TP1 ;
No more than 1 missed dose per TP ;
No more than 2 mi ssed doses allowed in TP1 through TP4;
Participants can onl y miss or have an  incomplete dose for either the first or se cond 
dose in TP4 (but not both) .
A delay ed treatment dose should be administered once the AE is resolved if the dose can be 
administered no later than [ADDRESS_705577] .  Once 7 day s passes from a regularl y scheduled dose, the delay ed dose in the 
previous 2 week dosing period will be considered missing (not delay ed), and shall not be 
administered.  For example, if the participant does not administer the investigational p roduct
on Monday  (July 1), but is able to resume treatment on Sunday  (July 8), the delay ed July 1 
dose may  be administered on July 8.  If the participant cannot resume treatment on July 8, the 
July 1dose will not be administered (recorded as a missed dose ), and the participant will 
receive the next regularl y scheduled dose on Monday (July 15). 
7.1.2. Permanent Discontinuation
Participants who experience a serious infectious AE ( eglife-threatening, requiring 
hospi[INVESTIGATOR_059], documented COVID -19, etc.) or sepsis should be permanently  discontinued
from study  treatment.   
PF-[ADDRESS_705578].  
7.2.Participant Discontinuation/Withdrawal From the Study 
A participant may  withdraw from the study  at an y time at his/her own request.
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted.  See the SoA for assessments to be collected at the time of study  
discontinuation and follow- up and for an y further evaluations that need to be completed. 
The early  discontinuation visit app lies only  to participants who are enrolled in the study  or 
those who are randomized and then are prematurely  withdrawn from the study .  Participants 
should be questioned regarding their reason for withdrawal.  The participant will be 
permanentl y discontinu ed both from the investigational product and from the study  at that 
time.
If a participant withdraws from the study , he/she may  request destruction of any  remaining 
samples taken and not tested, and the investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from the study  and also withdraws consent (see below) for 
disclosure of future information, no further evaluations should be performed and no 
additional data should be colle cted.  The sponsor may  retain and continue to use any  data 
collected before such withdrawal of consent.
Lack of completion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so long as the participant’s s afety was preserved.
Withdrawal of Consent: 
Participants who request to discontinue receipt of study  treatment will be discontinued from 
the study .  The onl y exception to this is when a participant specifically withdraws consent for 
any further contact [CONTACT_541177].  Participants should notify the investigator in writing of the decision 
to withdraw consent from future follow-up, whenever possible.  The withdrawal of consen t 
should be explained in detail in the medical records by  [CONTACT_093], as to whether the 
withdrawal is only  from further receipt of investigational product or also from study  
procedures and/or post treatment study  follow -up, and entered on the appropr iate CRF page.  
In the event that vital status (whether the participant is alive or dead) is being measured, 
publicly  available information should be used to determine vital status only as appropriately  
directed in accordance with local law.
Please reference Appendix [ADDRESS_705579] be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact [CONTACT_288949]/or 
should continue in the study .
Before a participant is deemed lost to follow-up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods).  These contact [CONTACT_541178]’s medical record.
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
Discontinuation of specific sites or of the study  as a whole is handled as part of Appendix 1.
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y-specific procedures.  
Study  procedures and their timing are summariz ed in the SoA.  Protocol waivers or 
exemptions are not allowed.
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or discontinue 
investigational product.
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potentia l 
participants meet all eligibility  criteria.  The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of the ICD may be utilized for screening or baseline 
purposes provided the procedures met the protocol -specified criteria and were performed 
within the time frame d efined in the SoA .
PF-[ADDRESS_705580] information will be provided to the investigator site prior 
to initiation of the study .
The total blood sampling volume for individual partic ipants in this study  is approximately  
350 mL .  The actual collection times of blood sampling may  change.  Additional blood 
samples may  be taken for safet y assessments at times specified b y [COMPANY_007], provided the total 
volume taken during the study  does not e xceed 550 mL during an y period of 60 consecutive 
days.
8.1.Efficacy Assessments
Efficacy  measures are not included as endpoints in this study  design. (see SoA).
8.2.Safety Assessments
Planned time points for all safety  assessments are provi ded in the SoA .  Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  concerns.
8.2.1. Physical Examinations
A complete ph ysical examination will include assessments of gen eral appearance, skin 
(including presen ce of rash), head, ey es, ears, nose and throat (HEENT), l ymph nodes, 
cardiovascular, respi[INVESTIGATOR_696], gastrointestinal, musculoskeletal and neurological sy stems.  
Investigators should pay  special attention to clinical sig ns related to previous serious 
illnesses. 
8.2.2. Vital Signs
Body temperature, pulse rate, respi[INVESTIGATOR_697], and blood pressure will be assessed as detailed 
in the SoA table.  Height and body  weight will also be measured and recorded.
Pulse rate and supi[INVESTIGATOR_9204] (in the participant’s arm and recorded to the nearest 
mmHg) measurements will be assessed with an automated device.  Manual techniques will 
be used onl y if an automated device is not available.
Blood pressure and pulse rate measurements should be preceded b y at least [ADDRESS_705581] 
for the participant in a quiet setting without distractions (eg, television, cell phones).
PF-[ADDRESS_705582] radiograph (lateral and posterior -anterior view chest X -rays) will be obtained at the 
Screen ing Visit in all participants, unless it has been taken and documented within [ADDRESS_705583] be 
negative for active tuberculosis infection, fungal infection, or an y other clinically  significant 
abnormalities unless the TB infection (evident b y scar or granuloma) has been successfull y 
treated (see Section 5.2Exclusion Criteria). If a chest CT exam (or an alternative chest 
imaging) is performed within [ADDRESS_705584] x -ray is not required at 
Screening.
8.2.4. Electrocardiograms
12-Lead ECG is onl y required at Screening to determine participant’s eligibility , see SoA
section of this protocol.  ECG should be performed after the participant has rested quietl y for 
about 10 minutes in a supi[INVESTIGATOR_541153] b y the personnel acquiring ECG 
tracings. ECGs will be read locall y. Participants with a screening 12-lead electrocardiogram 
that demonstrates clinically  significant abnormalities requiring urgent treatment (eg, acute 
myocardial infarction, serious tachy -or brady arrhy thmias) or that is indicative of serious 
underly ing heart d isease (eg, cardiomy opathy , major congenital heart disease, low voltage in 
all leads) should not be enrolled in the study .  These participants should be referred to a 
specialist for further assessment.
ECG values of potential clinical concern are listed in Appendix [ADDRESS_705585] any  
clinically  relevant changes occurring during the study  in the AE section of the CRF.  
Clinically  significant abnormal laboratory  findings are those which are not associ ated with 
the underl ying disease, unless judged by  [CONTACT_78259]'s condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within [ADDRESS_705586] should be repeated until the values return to normal or baseline or are no longer 
considered clinically  significant by  [CONTACT_10982].
If such values do not return to norma l/baseline within a period of time judged reasonable by  
[CONTACT_093], the etiology  should be identified and the sponsor notified.
PF-[ADDRESS_705587] be conducted 
in accordance with the laboratory  manual and the SoA.
If laboratory  values from non- protocol -specified laboratory  assessments performed at the 
institution’s local laboratory  require a change in participant managem ent or are considered 
clinically  significant b y the investigator (eg, SAE or AE or dose modification), then the 
results must be recorded in the CRF.
8.2.6. QuantiFERON-TB Gold In -Tube Test 
QuantiFERON-TB Gold I n-Tube test (QFT) is an in vitro indirect diagnostic test for 
M.tuberculosis infection (including disease) and is intended for use in conjunction with risk 
assessment, radiograph y (and or alternative imaging) and other medical and diagnostic 
evaluations. Screening Quanti FERON-TB Gold I n-Tube test must be performed in every  
participant within [ADDRESS_705588] according to loca l practice (eg, pulmonologist or infectious disease specialist) for 
further evaluation of latent TB, active TB or false positive QFT test result , unless they  have a 
past history  of having been adequatel y treated with appropriate chemoprohylaxis for latent 
TB or have completed treatment for active TB previously , in which case re -testing is not 
required. Participants who test positive and are considered to have current latent TB can 
enroll in the study  if they are on chemophroph ylaxis for at least 4 weeks.  (see Section 5.2
and Section 6.5). 
8.2.7. Pregnancy Testing
Pregnancy  tests may  be urine or serum tests, but must have a sensitivity  of at least 
25mIU/mL.  Pregnancy  tests will be performed in all WOCBP at the times listed in the SoA.  
Following a negative pregnancy  test result at screening, appropriate contraception mus t be 
commenced and a second negative pregnancy test result will be required at the baseline visit 
prior the participant’s receiving the adalimumab.  Pregnancy  tests will also be done whenever 
1 menstrual cy cle is missed during the active treatment period ( or when potential pregnancy  
is otherwise suspected) and at the end of the stud y.  Pregnancy tests may also be repeated if 
requested b y institutional review boards (IRBs)/ethics committees (ECs) or if required b y 
local regulations.  If a urine test cannot b e confirmed as negative (eg, an ambiguous result), a 
serum pregnancy  test is required.  In such cases, the participant must be excluded if the 
serum pregnancy result is positive.
8.2.8. Viral Disease Screening 
HBsAg, HBcAb, HBsAb and HCVAb testing is required to determine eligibility .  Hepatitis 
testing will be performed by  [CONTACT_6626].  Participants who are negative for all tests are 
eligible. Participants with positive HCVAb will be reflex tested for HCV RNA and will be 
eligible to participate if HCV RNA r esults are negative.  Participants with positive HBsAg or 
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 51HBcAb without positive HBsAb results are not eligible to participate in the study .  
Participants with negative HBcAb and HBsAg results but positive HBsAb are eligible to 
participate in the stud y. 
HIV (HIV-1 Ab and HIV -2 Ab) testing is also required to demonstrate eligibility  unless not 
permitted by  [CONTACT_427].  HIV testing will be performed by  [CONTACT_541179] a local lab is required per local regulations.  HIV testing will be completed at 
Screening unless testing has been performed within [ADDRESS_705589] result is suspected, additional testing may  be done in 
the central or local laborat ory to confirm thatparticipants are not positive for HIV, 
hepatitis B or hepatitis C.
8.3. Adverse Events and Serious Adverse Events
The definitions of an AE and an SAE can be found in Appendix 3 .
AEs will be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or 
the participant's legall y authorized representative).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether it 
meets the criteria for classification as an SAE or that caused the participant to discontinue the 
study  (see Section 7). 
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow -up 
information in an expedite d fashion.
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving investigational product), through and including 
a minimum of [ADDRESS_705590].
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.
Follow -up by  [CONTACT_74095] a level acceptable to the investigator, and 
[COMPANY_007] concurs with that assessment.
Investigators are not obligated to activel y seek AEs or SAEs after conclusion of the study  
participation .  However, if the investigator learn s of any  SAE, including a death, at an y time 
after a participant has been discharged from the study , and he/she considers the event to be 
PF-[ADDRESS_705591] 
promptly  notify  the sponsor.
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period are reported to [COMPANY_007] 
Safety  on the CT SAE Report Form i mmediatel y and unde r no circumstance should this 
exceed 24 hours, as indicated in Appendix 3 .  The investigator will submit any  updated SAE 
data to the sponsor within 24 hours of it being available.
SAEs occurring in a participant after the activ e collection period has ended are reported to 
[COMPANY_007] Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable possibility  of being related to investigational 
product must be reported to [COMPANY_007] Safety .
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period as 
described in Section [IP_ADDRESS] are recorded on the AE section of the CRF.  
The investigator is to record on the CRF all directly  observed and all spontaneously  reported 
AEs and SAEs reported by  [CONTACT_2299].
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 .
Care will be taken not to introduce bias when detecting AEs and/or SAEs.  Open- ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y foll ow each 
participant at subsequent visits/contacts.  For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality .  An y information relevant to the event, such as concomitant medications 
and illnesses, must be provided.  In the case of a participant death, a summary of availabl e 
autopsy  findings must be submitted as soon as possible to [COMPANY_007] Safety . 
Further information on follow -up procedures is given in Appendix [ADDRESS_705592] under clinical investigation.  
The sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the reg ulatory  authorit y, institutional review boards (IRBs)/ethics committees 
(ECs) , and investigators.
Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]Rs) according to local regulatory  requirements and sponso r policy  and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing an SAE or other 
specific safet y information (eg, summary or listing of SAEs) from the sponsor will review 
and then file it along wit h the investigator’s brochure and will notify the IRB/EC, if 
appropriate according to local requirements.
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure
Exposure to the investigational product under study  during pregnancy  or breastfe eding and 
occupational exposure are reportable to [COMPANY_007] Safety  within 24 hours of investigator 
awareness.
[IP_ADDRESS]. Exposure During Pregnancy
Details of all pregnancies in female participants and female partners of male participants will 
be collected after the star t of investigational product and until (50 - 100 days) after the last 
dose that is at least 5 terminal half- lives.
If a pregnancy  is reported, the investigator should inform the sponsor within [24 hours] of 
learning of the pregnancy  and should follow the p rocedures outlined in Appendix 4.
Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy ) are considered SAEs.
[IP_ADDRESS]. Exposure During Breastfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to [COMPANY_007] Safet y within 24 hours of the investigator’s awareness, using the 
CT SAE Report Form.  An exposure during breastfeeding report is not created when a [COMPANY_007]
drug specifically  approved for use in breastfeeding women (eg, vitamins) is administered in 
accord with authorized use.  However, if the infant experiences an SAE associated with such 
a drug’s administration, the SAE is reported together with the exposure during breastfeeding.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact [CONTACT_8898], which may  or may  not lead to the occurrence of an AE.
An occupational exposure is reported to [COMPANY_007] Safety  within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the information does not pertain to a participant enrolled in the study , the 
information is not recorded on a CRF; however, a copy  of the completed CT SAE Report 
Form is maintained in the investigator site file.
8.3.6. Cardiovascular and Death Events
Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported 
with TNF blockers. Cases of worsening CHF have also been observed with HUMI RA.
HUMI RA has not been formally  studied in patients with CHF; however, in clinical trials of 
another TNF blocker, a higher rate of serious CHF-related adverse reactions was observed. 
Exercise caution when using HUMIRA in patients who have heart failure and monitor them 
carefully .
8.3.7. Medical Device Incidents (Including Malfunctions)
Medical devices are being provided for use in this study  for the purposes self -administer 
adalimumab injections .  In order to fulfill regulatory reporting obligations worldwide, the 
investigator is responsible for the detection and documentation of events meeting the 
definitions of incident or malfunction that occur duri ng the stud y with such devices.
The definition of a medical device incident can be found in Appendix 7.
NOTE: Incidents fulfilling the definition of an AE/SAE will also follow the processes 
outlined in Section 8.3.1 and Appendix 3 of the protocol.
[IP_ADDRESS]. Time Period for Detecting Medical Device Incidents
Medical device incidents or malfunctions of the device that result in an incident will be 
detected, documented, and reported during all periods of the study  in which the medical 
device is used.
If the investigator learns of an y incident at an y time after a partici pant has been discharged 
from the study , and such incident is considered reasonably  related to a medical device 
provided for the stud y, the investigator will promptly  notify  the sponsor.
The method of documenting medical device incidents is provided in Appendix 7.
[IP_ADDRESS]. Follow -up of Medical Device Incidents
All medical device incidents involving an AE will be followed and reported in the same 
manner as other AEs (see Section 8.3.3).  This applies to all participants, including those who 
discontinue investigational product.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 55The investigator is responsible for ensuring that follow- up includes an y supplemental 
investigations as indicated to elucidate the nature and/or causality  of the incident.
New or updated information will be recorded on the originally  completed form with all 
changes signed and dated by  [CONTACT_093].
[IP_ADDRESS]. Prompt Reporting of Medical Device Incidents to Sponsor
Medical device incidents will be reported to the sponsor within [ADDRESS_705593] for the receipt of medical device reports and SAEs.
[IP_ADDRESS]. Regulatory Reporting Requirements for Medical Device Incidents
The investigator will promptly  report all incidents occurring with any  medical device 
provided for use in the study  in order for the sponsor to fulfill the legal responsibility  to 
notify  appropriate regulatory  authorities and other entities about certain safety  information 
relating to medical devices being used in clinical studies.
The investigator, or responsible person according to local requirements (eg, the head of the 
medical institution), will comply  with the applicable local regulatory  requirements relating to 
the reporting of incidents to the I RB/EC.
8.3.8. Medication Errors
Medication errors may  result from the administration or consumption of the investigational 
product b y the wrong participant, or at the wrong time, or at the wrong dosage strength.  
Additional examples of a medication error includes, but not limited to: outside the dosing 
window as per SoA,drug dispensing error, administration of two injections on the same day , 
incorrect route of administration, wrong m edication ty pe taken by  [CONTACT_3445].
Exposures to the investigational product under study  may  occur in clinical trial settings, such 
as medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form to [COMPANY_007] Safety Within 
24Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Medication errors include:
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 56Medication errors involving participant exposure to the investigational product;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study  participant.
Such medication errors occurring to a study participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page .
In the event of a medication dosing error, the sponsor should be notified immediately .
Whether or not the medication error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication error is recorded on the medication error page of the CR F and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on an AE page of the 
CRF.
Medication errors should be reported to [COMPANY_007] Safety within [ADDRESS_705594] SAE Report 
Form only when associated with an SAE.
8.4.Treatment of Overdose
For this study , any  injection of adalimumab with a dose greater than 10 mg/kg will be 
considered an overdose. This is based on information included in the Humira USPI1which 
indicates that m ultiple doses of up to 10 mg/kg IV have been administered to patients in 
clinical trials without evidence of dose -limiting toxicities.  Based on an average absolute 
bioavailability  estimate of 64% from t hree studies in which a single 40 mg SCdose was 
administered, this would conservativel y (based on a body weight of 40 kg) equate to an 
approximately  15-fold higher dose than the 40 mg injection used in the protocol.  The 
investigational products used in t his study  will follow Humira’s USPI /SmPC. [COMPANY_007] does not 
recommend specific treatment for an overdose. 
In the event of an overdose, the investigator should:
1.Contact [CONTACT_10990] .
2.Closely  monitor the participant for an y AEs/SAEs and laboratory  abnormalities until 
adalimumab can no longer be detected s ystemically  (at least 70 day s).  Appropriate 
treatments to relieve the sy mptoms should be provided to the participant. 
3.Obtain a blood sample for pharmacokinetic (PK) analy sis within [ADDRESS_705595] if requested b y the medical monitor 
(determined on a case -by-case basis).
4.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
5.Overdose is reportable to Safety  only when associated with an SAE.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 57Decisions regarding dose interruptions or modifications will be made by  [CONTACT_78256].
8.5.Pharmacokinetics 
Blood samples of approximately  6mL, to provide a minimum of 1 mL  of serum per aliquot
(2 total) , will be collected for measurement of serum concentrations of adalimumab as 
specified below.
Samples for determination of adalimumab trough drug concentrations will be 
collected within [ADDRESS_705596] administration on Weeks 
22, 24, 26, 28 , and on Day 1 (time 0), Weeks [ADDRESS_705597]
administration (ie ,pre-dose) .
Primary  endpoint data will be supported by  [CONTACT_541180] 2 -week PK Profile.
The 2 -week PK sampling period starts with Week 30 pre-dose PK collection and ends 
with Week 32 pre -dose PK collection.
Pre-dose PK collection at Week 30/ PK Profile Day  1, the b lood sample will be 
collected within [ADDRESS_705598] administration.
For the subsequent PK Profil e Day s, post -Week 30 dosing times for serum 
collections are :
48 (+ 4) hrs on PK Profile Day  3, 
72 (+ 6) hrs on PK Profile Day  4, 
96 (+ 8) hrs on PK Profile Day  5, 
144 (+ 8) hrs on PK Profile Day  7, 
240 (+ 24) hrs on PK Profile Day  11, and 
336 (+ 24) hrs on PK Profile Day  15; before Week 32 dosing . 
The 2 -week PK Profile collections may  be completed using home health care service.  Please 
reference Table 1. PK Sampling Table .In order for participant’s PK Profile to be 
included in the primary  analy sis every effort should be made to draw samples within the 
specified time windows .
Serum samples for PK assessment will be anal yzed using a validated enzyme linked 
immunosorben t assay  (ELISA) to quantitatively  measure concentrations of Humira and 
PF-06410293.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 58For detailed PK sample collection and processing instructions, please see the study  
laboratory  manual.
8.6.Pharmacodynamics
Pharmacod ynamic (PD) parameters are not evaluated in this study .
8.7.Genetics
8.7.1. Specified Genetics
Genetics are not evaluated in this study .
8.7.2. Banked Biospecimens for Genetics
There are no Banked Biospecimens for Genetics in this study  as per all other Biosimilar 
programs.
8.8.Biomarkers
Biomarkers are not evaluated in this study .
8.8.1. Specified Gene Expression (RNA) Research
Specified gene expression ribonucleic acid (RNA) research is not included in this study .
8.8.2. Specified Protein Research
Specified protein research is not included in this study .
8.8.3. Specified Metabolomic Rese arch 
Specified metabolomic research is not included in this study .
8.8.4. Banked Biospecimens for Biomarkers
There are no Banked Biospecimens for Biomarkers in this study .
8.9.Immunogenicity Assessments
8.9.1. Analysis of Anti -adalimumab Antibodies and Neutralizing Anti -adalimumab 
Antibodies
Blood samples will be collected at the time points specified in the SoA table to determine the 
presence of ADA and neutralizing antibodies (NAb), concurrently with samples for PK analysis in 
Treatment Periods 1 t hrough 4.   For detailed ADA and NAb sample collection and processing 
instructions, please see the study  lab manual.
Serum samples for ADA assessment will be anal yzed using a validated 
electrochemoluminescent (ECL ) immunoassay  using PF -06410293 as a capture agent.  
Samples positive for ADA will be further tested for neutralizing activity  using a validated 
cell-based NAb assay  that utilizes PF -06410293 as the capture agent. 
PF-06410293
Protocol B5381012Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 59 
 
 
 
8.10. Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study.
9. STATISTICAL CONSIDERATIONS
Detailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in a statistical analysis plan (SAP), which will be maintained by [CONTACT_456].  The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.
9.1. Estimands and Statistical Hypotheses
9.1.1. EstimandsThe primary estimands are the geometric mean ratio (GMR) and 90% confidence interval 
(CI) for AUC
τand C max to evaluate the PK equivalence between the switching and 
non-switching arms, after 3 switches, in participants with RA who meet the PK population criteria, that include criteria for the number and timing of missing doses, availability of PK data, adherence to background therapy, and major protocol deviations related to PK assessment ( Section 9.3 ).
9.2. Sample Size Determination
Assuming a GMR (switching arm vs non-switching arm) of 105% and a coefficient of 
variation (CV) of 55% for each of the PK parameters, AUC
τand C max, an anticipated 
non-evaluable rate of 25%, and a correlation of 0.5 between log-transformed AUC τand log 
transformed C max, a total sample size of approximately 420 participants (314 evaluable 
participants) would provide 85% power to demonstrate that the 90% CI for the GMR is within 80.00% to 125.00% for both parameters. 
The %CV assumption for the power calculation was derived from data on 15 RA participants 
receiving MTX who participated in a PK substudy of an innovator study,
3with %CV of 
53% and 56% for AUC τand Cmax, respectively,4and from 21 RA participants (6 on MTX) 
who participated in a PK substudy of the innovator open-label extension study, where %CV CCI
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 60forall participants was 48% and 49%, and for MTX only  was 46% and 44%, for AUC and 
Cmax, respectivel y.
9.3.Populations for Analysis
The PK Population is defined as all randomized participants who are dosed to initiate the 
Week 30 stead y state PK profile, remain on background MTX with no major protocol 
deviations influencing the PK assessment, such as a missing dose (the first dose of the stud y 
in TP1 cannot be missed, no more than [ADDRESS_705599] or second dose in TP4 (but not 
both), and the study  doses on Weeks 26, 28, and 30 cannot be missed or incomplete ),and
have at least 1 primary  endpoint (AUC or C max).  The last study  dose in TP4 on week [ADDRESS_705600] swill be excluded from the PK population in case of 
missed PK sample(s) which significantly  affect the calculation of PK parameters.  The PK 
population will be used for the primary  PK analy sis and other secondary  PK endpoint 
analyses (Tmax, Cav,and CL /F).  
The Enrolled Population is defined as all participants who are enrolled in TP1.  This 
population will be used for participant accountability  in TP1.
The Safet y Population for TP1 (Safet y-TP1) is defined as all participants who are enrolled in 
TP1 and re ceive at least one dose of investigational product in TP1.  This population will be 
used for the TP1 safet y analy ses.
The Intent -to-Treat Population (I TT-Randomized) is defined as all participants who are 
randomized to a study  treatment group at Study  Week 10.  This population will be used for 
participant accountability during TP2 through TP4. 
The Safet y Population (Safet y-Randomized) is defined as all participants who are 
randomized and receive at least one dose of investigational product following the 
randomization at Study  Week 10.  The Safet y Population will be used for the safet y anal yses
during TP2 through TP4, ADA and NAb anal yses and the secondary  PK endpoint (C trough).
9.4. Statistical Analyses
The SAP will be developed and finalized before database l ock and will describe the 
participant populations to be included in the analy ses, and procedures for accounting for 
missing, unused, and spurious data.  This section is a summary  of the planned statistical 
analyses of the primary  and secondary  endpoints.
9.4.1. Efficacy Analyses
Efficacy  measures are not included in this study  design, therefore, efficacy  anal yses will not 
be performed.  
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 619.4.2. Safety Analyses
Safety  anal yses for TP1 will be performed using the Safet y-TP1 population for the Humira 
group.  Safet y analyses for TP2 through TP4 will be performed using Safety- Randomized 
populations by  [CONTACT_6660] (switching arm vs non -switching arm).  
[IP_ADDRESS]. Adverse Event
Adverse events will be classified using the medical dictionary  for regulatory  activities 
(MedDRA) classific ation sy stem.  
Adverse events (treatment- emergent adverse events; treatment -related adverse events; 
adverse events classified as Grade 3 or higher; and SAEs) will be summarized by  [CONTACT_541181] .  A t reatmen t-emergent 
adverse event (TEAE) is defined as any adverse event that occurs after the beginning of the 
study  treatment. 
Adverse events of special interest including opportunistic infections and immune -based 
adverse effects will be summarized using grouped Medical dictionary  for regulatory  
activities ( MedDRA )codes in addition to presentation of individual AE preferred terms. 
Immune -based adverse effects may  be both acute and delay ed and include injection -site 
reactions (I SRs), AEs that fulfill Sampson Cri teria,4and AEs identified as potential 
hypersensitivity /anaph ylactic reactions using a System Medical Dictionary  for Drug 
Regulatory  Activities (MedDRA )standardized MedDRA query (SMQ) that occur in r elation 
to the administration of the study  drug.  Adverse events recorded on the CRF as ISRs will be 
summarized both as individual event symptoms and as a group for the purpose of comparing 
the overall incidence of ISRs.  Therefore, the following safet y endpoints will be summarized 
for all participants, and for ADA positive and negative subgroups: 
Participants with I SRs (as per the investigators); 
Participants with AEs that fulfill Sampson’s Criteria;
Participants with AEs belonging to SMQ broad groupi[INVESTIGATOR_541154]  / anaphylactic reactions.  
[IP_ADDRESS]. Laboratory Test Abnormalities
Hematology  and chemistry  laboratory  data will be summarized at week [ADDRESS_705601] after 
randomization in TP2.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Prior and Concomitant Mediations
Prior medications and concomitant medications will be coded b y WHO medical dictionary . 
Participants who received these medications will be listed and summarized.
9.4.3. Other Analyses 
[IP_ADDRESS]. Pharmacokinetics Analysis
The serum concentrations between Week [ADDRESS_705602] non -compartmental anal ysis to estimate the PK p arameters for 
each individual participant. The PK parameters (C max, AUC , Tmax,Cav,and CL/F), and the 
serum concentrations will be summarized descriptively . 
Interchangeability will be assessed b y constructing the point estimate (GMR) and the 
90% CIs for the GMR for the primary  endpoints, C maxand AUC .  Interchangeability will be 
established statistically  if the 90% CI for the GMR is within 80.00% to 125.00% for both 
endpoints.  The GMR and CI  will be obtained using anal ysis of variance (ANOVA) applied 
to log -transformed data, with terms for treatment and randomization stratification factor 
(body  weight categories).
Additionally , adalimumab trough concentration data (C trough) will be summarized using 
descriptive statistics (mean, standard deviation, median, minimum, and maximum) by  
[CONTACT_541182].
[IP_ADDRESS]. ADA and NAb Analysis
For the ADA and NAb data, the percentage of participants with positive ADA and NAb will 
be calculated and summarized for the safety -randomized population by  [CONTACT_541183] t in 
Treatment Period s.  For participants with positive ADA and NAb, the magnitude (titer), time 
of onset, and duration of ADA and NAb response will also be described.  In addition, the 
impact of ADA and NAb on PK over time will be assessed for each treatment arm.
[IP_ADDRESS]. Other Endpoint Analysis
Demographic and baseline characteristics, such as participant age, sex, height, weight, race, 
ethnicity , MTX dose, and medical history  will be tabulated and su mmarized using descriptive 
statistics. Investigational product administration will be summarized.
9.5.Interim Analyses
No formal interim anal ysis will be conducted for this study .As this is an open -label
study ,the sponsor will conduct ongoing reviews of the data during the course of the study  for 
the purpose of safet y.
9.5.1. Data Monitoring Committee 
This study  will not use a data monitoring committee (DMC).
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 6310. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declaration of H elsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines;
Applicable International Council for Harmonisation (I CH) Good Clinical Practice 
(GCP) guidelines;
Applicable laws and regulations, including a pplicable privacy  laws.
The protocol, protocol amendments, ICD, investigator’s brochure (IB), and other relevant 
documents (eg, advertisements) must be reviewed and approved by  [CONTACT_177269] I RB/EC by  [CONTACT_20003] b y the IRB/EC 
before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC;
Notify ing th e IRB/EC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 Code of Federal Regulations (CFR), I CH guidelines, the I RB/EC, 
European regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations.
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the investigational 
product, [COMPANY_007] should be informed immediately. 
PF-[ADDRESS_705603], and 
of an y serious breaches of this protocol or of ICH GCP that the investigator b ecomes aware 
of.
10.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statem ents to the appropriate regulatory  authorities.  I nvestigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/he r representative will explain the nature of the study  to the 
participant or his/her legally  authorized representative and answer all questions regarding the 
study .
Participants must be informed that their participation is voluntary .  Participants or their 
legally  authorized representative will be required to sign a statement of informed consent that 
meets the requirements of [ADDRESS_705604] (HIPAA) requirements, where applicable, and the IRB/EC 
or study  center.
The investigator must ensure that each study  participant or his or her legally  authorized 
representative is fully  informed about the nature and objectives of the study , the sharing of 
data related to the study , and possible risks associated with participation, including the risks 
associated with the processing of the participant’s personal data. 
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_32855] h local data protection law.  The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may  be examined by  [CONTACT_541184], by  
[CONTACT_6667]/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  participant or his or her legall y 
authorized representative is fully  informed about his or her right to access and correct his or 
her personal data and to withdraw consent for the processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the dat e the written consent was obtained.  
The authorized person obtaining the informed consent must also sign the ICD.
Participants must be reconsented to the most current version of the ICD(s) during their 
participation in the study .
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 65A cop y of the ICD(s) must be provided to the participant or the participant’s legall y 
authorized representative.
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protecti on of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic form and 
will be password protected to ensure that onl y authorized study  staff have access.  The study  
site will implement appropriate technical an d organizational measures to ensure that the 
personal data can be recovered in the event of disaster.  In the event of a potential personal 
data breach, the stud y site shall be responsible for determining whether a personal data 
breach has in fact occurred and, if so, providing breach notifications as required by  [CONTACT_2371].
To protect the rights and freedoms of natural persons with regard to the processing of 
personal data, participants will be assigned a single, participant -specific numerical code.  
Any particip ant records or data sets that are transferred to the sponsor will contain the 
numerical code; participant names will not be transferred.  All other identifiable data 
transferred to the sponsor will be identified by  [CONTACT_20007], participant -specific code.  The 
study  site will maintain a confidential list of participants who participated in the study , 
linking each participant’s numerical code to his or her actual identity .  In case of data 
transfer, the sponsor will protect the confidentiality of participants ’ personal data consistent 
with the clinical study agreement and applicable privacy  laws.
10.1.5. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Trials 
Database (EudraCT), and/or www.pfizer.com, and other public registries in accordance with 
applicable local laws/regulations.  I n addition, [COMPANY_007] reports study  results outside of the
requirements of local laws/regulations pursuant to its standard operating procedures (SOPs).
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial US Basic Results on www.clinicaltrials.gov for [COMPANY_007] -sponsored 
interventional studies (conducted in patients) that evaluate the safet y and/or efficacy of a 
product, regardless of the geographical location in which the study is conducted.  US Basic 
Results are generall y submitted for posting within 1 year of the primary completion date 
(PCD) for studies in adult populations or within [ADDRESS_705605]
[COMPANY_007] posts European Union (EU) Basic Results on EudraCT for all [COMPANY_007] -sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted 
for posting within 1 year of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric populations.
www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses clinical study  report (CSR )synopses in which any  
data that could be used to identify  individual participants have been removed) on 
www.pfizer.com for [COMPANY_007]-sponsored interventional studies at the same time the US Basic 
Results document is posted to www.clinicaltrials.gov.
Documents within marketing authorization packages/submissions
[COMPANY_007] complies with the European Union Policy  0070, the proactive publication of clinical 
data to the European Medicines Agency  (EMA) website.  Clinical data, under Phase 1 of this 
policy , includes clinical overviews, clinical summaries, CSRs, and appendices containing the 
protocol and protocol amendments, sample CRFs, and statistical methods.  Clinical data, 
under Phase 2 of this policy , includes the publishing of individual participant data.  Policy  
0070 applies to new marketing authorization applications submitted via the centralized 
procedure since 01 January 2015 and applications for line extensions and for new indications 
submitted via the centralized procedure since 01 July  2015.
Data Sharing
[COMPANY_007] provides researchers secure access to patient-level data or full C SRs for the purposes 
of “bona -fide scientific research” that contribute to the scientific understanding of the 
disease, target, or compound class.  [COMPANY_007] will make available data from these trials 
24months after study  completion.  Patient -level data will be anon ymized in accordance with 
applicable privacy  laws and regulations.  CSRs will have personall y identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analyses.  Research teams must include a biostatistician.  Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 6710.1.6. Data Quality Assurance
All participa nt data relating to the stud y will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data).  The investigator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_20010].
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must ensure that the CRFs are securel y stored at the study site in encrypted 
electronic form and are password protected to prevent access b y unauthorized third parties.
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents. This 
verification may  also occur after study  completion.  I t is important that the investigator(s) 
and their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the proces s.
Monitoring details describing strategy  (eg, risk- based initiatives in operations and quality  
such as risk management and mitigation strategies and anal ytical risk- based monitoring), 
methods, responsibilities, and requirements, including handling of nonc ompliance issues and 
monitoring techniques (central, remote, or on -site monitoring), are provided in the 
monitoring plan.
The sponsor or designee is responsible for the data management of this study , including 
quality  checking of the data.
Study  monitors w ill perform ongoing source data verification to confirm that data entered 
into the CRF by  [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the s tudy is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP, and all applicable regulatory  requirements.
Records and documents, including signed ICDs, pertaining to the conduct of this study  must 
be re tained b y the investigator for [ADDRESS_705606] ensure that the records continue to be stored securel y for as long as they are 
maintained.
When participant data are to be deleted, t he investigator will ensure that all copi[INVESTIGATOR_78245] y deleted from all systems.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 68The investigator(s) will notify the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study .  Furth ermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection.  The 
investigator site and investiga tor will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant's medical records.  The investigator will promptly  
provide copi[INVESTIGATOR_19946].  Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected.  Source documents are filed at the investigator site.
Data reported on the CRF or entered in the electronic CRF (eCRF) that are transcribed from 
source documents must be consistent with the source document s or the discrepancies must be 
explained.  The investigator may need to request previous medical records or transfer 
records, depending on the study .  Also, current medical records must be available.
Definition of what constitutes source data can be found in the Study  Binder.
10.1.8. Study and Site Closure
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor.  Study  sites will be closed upon 
study  completion.  A study site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the contract 
research organiz ation (CRO) if requested to do so by  [CONTACT_22846]/EC or if such 
termination is required to protect the health of study participants.
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the inve stigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or GCP guidelines;
Inadequate recruitment of participants by  [CONTACT_093];
Discontinuation of further investigational product development.
Study  termination is also provided for in the clinical study  agreement.  If there is any  conflict 
between the contract and this protocol, the contract will control as to termination rights.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 6910.1.9. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_8860]'s appropriately  qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_541185].  
To facilitate access to appropriatel y qualified medical personnel on stud y-related medical 
questions or problems, participants are provided with a contact [CONTACT_1137].  The contact [CONTACT_95504], at a minimum, protocol and investigational product identifiers, participant numbers, 
contact [CONTACT_22850], and contact [CONTACT_4664] a contact [CONTACT_366323] r in the 
event that the investigator site staff cannot be reached to provide advice on a medical 
question or problem originating from another healthcare professional not involved in the 
participant’s participation in the study .  The contact [CONTACT_74073]; however, it should be used 
only in the event that the established communication pathway s between the investigator site 
and the study  team are not available.  It is therefore intended to augment, but not replace, the 
established communication pathway s between the investigator site and the study  team for 
advice on medical questions or problems that may arise during the stud y.  The contact 
[CONTACT_22853] , and if a participant calls that 
number, he or she will be directed back to the investigator site.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 7010.2. Appendix 2: Clinical Laboratory Tests
The following safet y laboratory  tests will be performed by  a central laboratory  at times 
defined in the SoA section of this protocol.  Additional laboratory  results may  be reported on 
these samples as a result of the method of analy sis or the ty pe of anal yzer used by  [CONTACT_332854] ; or as derived from calculated values.  These additional tests would not require 
additional collection of blood.  Unscheduled clinical laboratory  measurements may  be 
obtained at an y time during the study  to assess any  perceived safety  concerns.
Table 4.Protocol -Required Safety Laboratory Assessments
Hem atology Chemistry Urinalysis Other
Hem oglobin
Hem atocrit
RBC count
MCV
MCH
MCHC
Platelet count
WBC count
Total neutrophils 
(Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)BUN
creatinine
Calcium
Sodium
Potassium
Chloride
Total 
CO 2(bicarbonate)
AST, ALT
Total bilirubin
Alkaline phosphatase
Albumin
Total proteinpH
Glucose 
Protein 
Blood 
Ketones
Nitrites
Leukocyte esterase
Urobilinogen
Urine bilirubin
MicroscopyaAt screening only:
FSHb
Urine drug screening
Pregnancy test 
(β-hCG)c
Hepatitis B surface 
antigen
Hepatitis B core 
antibody
Hepatitis B surface 
antibody
Hepatitis C antibody
HCV RNAd
HIV-1 antibody
HIV-2 antibody
QuantiFERON-TB Gold 
In-Tube Test
Abbreviations: Abs = absolute; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
-hCG = beta -human chorionic gonadotropin; BUN = blood urea nitrogen; CO 2 = carbon dioxide; 
FSH = follicle -stimulating hormone; MCH = mean corpuscular hemoglobin; MCHC = mean 
corpuscular hemoglobin concentration; MCV = mean corpuscular volume; qual = qualitative; 
RBC =red blood cell; WBC = white blood cell. 
a.Only if urine dipstick is positive for blood, protein, nitrites, or leukocyte esterase.
b.For confirmation of postmenopausal status only.
c.Pregnancy testing at Screening in female participants of childbearing potential by [CONTACT_541186]. Pregnancy testing (HCG) after Screening will be performed locally using 
urine samples. Pregnancy testing may be repeated more frequently if required by [CONTACT_1744]/ECs or 
local regulations, or if potential pregnancy is suspected.
d.Required only if HCVAb test result is positive.
Investigators must document their review of each laboratory  safet y report.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 7110.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or cl inical study  
participant, temporall y associated with the use of investigational product , whether 
or not considered related to the investigational product.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally  associated with the use of investigational product.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator (ie, not related to progression of 
underly ing disease).
Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after investigational product administration 
even though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the cl inical sequelae of a suspected overdose of either 
investigational product or a concomitant medication.  Overdose per se will not be 
reported as an AE/SAE unless it is an intentional overdose taken with possible 
suicidal/self- harming intent.  Such overdoses should be reported regardless of 
sequelae.
Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 72The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condi tion.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/sy mptoms of the disease under study , death 
due to progression of disease).
An SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term “life -threatening” in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event.  I t does not refer to an event that 
hypothetically  might have caused death if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been ap propriate in the phy sician’s office or 
outpatient setting.  Complications that occur during hospi[INVESTIGATOR_1084].  If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious.  When in doubt as to whether “hos pi[INVESTIGATOR_059]” occurred or was necessary , the AE 
should be considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen from 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 73This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle) which may  interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediatel y life-threatening or result in death or hospi[INVESTIGATOR_402880].  These events 
should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug 
dependency  or drug abuse.
10.3.3. Recording/Reporting and Follow -up of AEs and/or SAEs
AE and SAE Recording/Reporting
The table below summarizes the requirements for recording adverse events on the CRF 
and for reporting serious adverse events on the Clinical Trial (CT) Serious Adverse Event 
(SAE) Report Form to [COMPANY_007] Safety .  These requirements are delineated for 3 ty pesof 
events: (1) SAEs; (2) nonserious adverse events (AEs); and (3) exposure to the 
investigational product under study  during pregnancy  or breastfeeding, and occupational 
exposure. 
It should be noted that the CT SAE Report Form for reporting of SAE inform ation is not 
the same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to [COMPANY_007] 
Safety Within [ADDRESS_705607] 
under study  during 
pregnancy  or 
breastfeeding, and 
occupational exposureNone All (and exposure during 
pregnancy  [EDP] 
supplemental form for 
EDP)  
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety  in lieu of completion of the CT SAE Report 
Form/AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] Safety.  In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_19953] .
The investigator will attempt to establish a dia gnosis of the event based on signs, 
symptoms, and/or other clinical information.  Whenever possible, the diagnosis 
(not the individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of i ntensity  for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
GRADE Clinical Description of Severity
1 MILD adverse event
2 MODERATE adverse event
3 SEVERE adverse event
4 LIFE -THREATENING consequences; urgent intervention indicated
5 DEATH RELATED TO adverse event
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 75Assessment of Causality
The investigator is obligated to assess the relationship between investigational 
product and each occurrence of each AE/SAE.
A “reasonable possibility” of a relationship convey s that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying di sease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to investigational 
product administration will be considered and investigated.
The investigator will also consult the investigator’s brochure (IB) and/ or product 
information, for marketed products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor.  However, it is 
very important that the investigator always make an assessment of causality 
for every event b efore the initial transmission of the SAE data to the sponsor.
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow- up report with the updated causality  
assessment.
The causality  assessment is on e of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the investigational product caused 
the event, then the event will be handled as “related to investigational product” for 
reporting p urposes, as defined by  [CONTACT_456].  In addition, if the investigator 
determines that an SAE is associated with study  procedures, the investigator must 
record this causal relationship in the source documents and CRF, and report such 
an assessment in the de dicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 76Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_55900]/or causalit y of the AE or SAE as fully as 
possible.  This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare p rofessionals.
If a participant dies during participation in the study or during a recognized 
follow -up period, the investigator will provide [COMPANY_007] Safet y with a cop y of any 
postmortem findings including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to the sponsor within 24 hours 
of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety  will be the 
electronic data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool ( see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data 
become available.
After the stud y is completed at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry of new data or changes to exist ing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to [COMPANY_007] Safety  by [CONTACT_756].
PF-[ADDRESS_705608] SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working, notification by  [CONTACT_20021] a cop y of the CT SAE Report Form sent by  [CONTACT_20022].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign t he CT SAE Report Form pages within the designated reporting 
time frames.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 7810.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information
10.4.1. Male Participant Reproductive Inclusion Criteria
According to Humira label (SmPC), no specific male contraceptive measures are mandated 
with Humira use, although male participants with WOCBP partners should be familiar with 
the following Humira SmPC recommendation: “Women of childbearing potential are 
strongl y recommended to use adequate contraception to prevent pregnancy and continue its 
use for at least 5months after the last Humira treatment”.2
10.4.2. Female Participant Reproductive Inclusion Criteria
According to Humira label (SmPC) , women of childbearing potential are strongl y 
recommended to use adequate contraception to prevent pregnancy  and continue its use for at 
least [ADDRESS_705609] 1 of the following conditions applies:
Is not a WOCBP (see definitions below in Section 10.4.3).
OR
Is a WOCBP and using an acceptable contraceptive method as described below 
during the intervention period (for at least [ADDRESS_705610]).  The investigator should evaluate the effectiveness of the 
contraceptive method in relationship to the first dose of investigational product .  
The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy . 
10.4.3. Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of investigational product, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Documented bilateral salpi[INVESTIGATOR_1656] ;
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 79Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion 
should be applied to determining study  entry .
Note: Documentation for any  of the above categories can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical history  interview.   The method of documentation should be recorded in the 
participant’s medical record for the stud y.
2.Postmenopausal female:
A postmenopausal state is defined as age 60 years or older or no menses for 
12 m onths without an alternative medical cause. 
A high follicle -stimulating hormone (FSH) level in the postmenopausal range 
may be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormone replacement therap y (HRT). 
Females on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highly effective contraception methods 
if they  wish to continue their HRT during the study .  Otherwise, they  must 
discontinue HRT to allow confirmation o f postmenopausal status before study  
enrollment.
10.4.4. Contraception Methods
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device (IUD).
3.Intrauterine hormone -releasing s ystem (IUS).
4.Bilateral tubal occlu sion.
5.Vasectomized partner:
Vasectomized partner is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the woman of childbearing potential and the 
absence of sperm has been confirmed.  If not, an additional effe ctive method of 
contraception should be used.  The spermatogenesis cy cle is approximately  
90days.
6.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation:
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 80oral;
intravaginal;
transdermal;
injectable.
7.Progestogen -only hormone contraception associated with inhibition of ovulation:
oral;
injectable.
8.Sexual abstinence:
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the investigational product.  The reliability  of sexual abstinence needs to be 
evaluated in relation to the duration of the stud y and the preferred and usual 
lifesty le of the participant.
9.Progestogen -only oral hormonal contracep tion where inhibition of ovulation is not the 
primary  mode of action.
10. Male or female condom with or without spermicide.
11. Cervical cap, diaphragm, or sponge with spermicide.
12. A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods).
Collection of Pregnancy Information
For both unapproved/unlicensed products and for marketed products, an exposure during 
pregnancy  (EDP) occurs if:
A female becomes, or is found to be, pregnant either while receiving or h aving been 
exposed (eg, because of treatment or environmental exposure) to the investigational 
product; or the female becomes or is found to be pregnant after discontinuing and/or 
being exposed to the investigational product;
An example of environmental exposure would be a case involving direct contact 
[CONTACT_4490] a [COMPANY_007] product in a pregnant woman (eg, a nurse reports that she is pregnant 
and has been exposed to chemotherapeutic products).
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 81A male has been exposed (eg, because of treatment or environmental exp osure) to the 
investigational product prior to or around the time of conception and/or is exposed 
during his partner’s pregnancy .
If a participant or participant’s partner becomes or is found to be pregnant during the 
participant’s treatment with the investigational product, the investigator must report this 
information to [COMPANY_007] Safety  on the CT SAE Report Form and an EDP supplemental form, 
regardless of whether an SAE has occurred.   In addition, the investigator must submit 
information regarding environme ntal exposure to a [COMPANY_007] product in a pregnant woman (eg, a 
participant reports that she is pregnant and has been exposed to a cytotoxic product b y 
inhalation or spi[INVESTIGATOR_4598]) to [COMPANY_007] Safety using the EDP supplemental form.  This must be done 
irrespective o f whether an AE has occurred and within 24 hours of awareness of the 
exposure.  The information submitted should include the anticipated date of delivery  (see 
below for information related to termination of pregnancy ).
Follow -up is conducted to obtain gene ral information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome as a 
follow -up to the initia l EDP supplemental form.  In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structur al 
integrit y of the terminated fetus should be assessed by [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
If the outcome of the pregnancy  meets the criteria for an SAE (ie, ectopic pregnancy , 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live-born bab y, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the 
investigator should follow the procedures for repo rting SAEs.
Additional information about pregnancy  outcomes that are reported to [COMPANY_007] Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarriage and missed abortion;
Neonatal deaths that occur within [ADDRESS_705611]. 
Additional information regarding t he EDP may  be requested by  [CONTACT_456].  Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).  In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner.  The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 8210.5. Appendix 5: Liver Safety: Suggested Actions and Follow -up Assessments 
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while thos e who show transient liver injury , but adapt 
are termed “adaptors.”  In some participants, transaminase elevations are a harbinger of a 
more serious potential outcome.  These participants fail to adapt and therefore are 
"susceptible" to progressive and ser ious liver injury , commonl y referred to as drug -induced 
liver injury  (DILI).  Participants who experience a transaminase elevation above 3 times the 
upper limit of normal ( ×ULN) should be monitored more frequentl y to determine if they  are 
an “adaptor” or are “susceptible.”
In the majority  of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransferase (ALT) precede total bilirubin (TBili) elevat ions (>2 × ULN) by  [CONTACT_74097].  The increase in TBili ty pi[INVESTIGATOR_1306] y occurs while AST/ALT is/are still elevated 
above 3 ×ULN (ie, AST/AL T and TBili values will be elevated within the same laboratory  
sample).  In rare instances, by  [CONTACT_541187], AST/AL T values might 
have decreased.  This occurrence is still regarded as a potential DILI.  Therefore, abnormal 
elevations in either AST OR AL T in addition to TBili that meet the criteria outlined below 
are considered potential DILI (assessed per Hy ’s law criteria) cases and should alway s be 
considered important medical events, even before all other possible causes of liver injury 
have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and underlying conditions.  Participants who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participants with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or no t available.
For participants with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT base line values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).
PF-[ADDRESS_705612]/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potentia l Hy’s law case should be reviewed with the sponsor.  
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_705613] and AL T and TBili for suspected cases of 
Hy’s law, additional laboratory  tests should include albumin, creatine kinase (CK), direct and 
indirect bilirubin, g amma -glutam yl transferase (GGT), prothrombin time (PT)/international 
normalized ratio (INR), total bile acids, and alkaline phosphatase.  Consideration should also 
be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for
further testing, as needed, for further contemporaneous anal yses at the time of the recognized 
initial abnormalities to determine etiology .  A detailed history , including relevant 
information, such as review of ethanol, acetaminophen (either b y itself or as a coformulated 
product in prescription or over -the-counter medications) , recreational drug, supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
[CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected.  Further testing for acute 
hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary  tract) and collection of 
serum sample for acetamino phen drug and/or protein adduct levels may  be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for t he liver function test (LFT) abnormalities has y et been found.  Such 
potential DILI (Hy’s law) cases are to be reported as SAEs, irrespective of availability 
of all the results of the investigations performed to determine etiology of the LFT 
abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 8410.6. Appendix 6: ECG Findings of Potential Clinical Concern
ECG Findings That May Qualify as Adverse Events (AEs)
Marked sinus brady cardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >280 msec.
New prolongation of QTcF to >480 msec (absolute) or by60msec from baseline.
New -onset atrial flutter or fibrillation, with controlled ventricular response rate:
ie,rate <120 bpm.
New -onset ty peI second -degree (Wenckebach) AV block of >30 seconds’ 
duration.
Frequent premature ventricular complexes (PVCs), triplets, or short intervals 
(<30 seconds) of consecutive ventricular complexes.
ECG Findings That May Qualify as Serious Adverse Events (SAEs)
QTcF prolongation >500 msec.
New ST -Tchanges suggestive of myocardial ischemia.
New -onset left bundle branch block (QRS >120 msec).
New -onset right bundle branch block (QRS >120 msec).
Symptomatic brady cardia. 
Asystole:
In awake, s ymptom -free patients in sinus rhy thm, with documented periods of 
asystole 3.0 seconds or any  escape rate <40 bpm, or with an escape rhy thm 
that is below the AV node; 
In awake, s ymptom -free patients wi th atrial fibrillation and brad ycardia 
with [ADDRESS_705614] 5 seconds or longer; 
Atrial flutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained supraventricular tach ycardia (rate >120 bpm) (“sustained” = short 
duration with relevant symptoms or lasting >1 minute).
Ventricular rh ythms >30 seconds’ duration, including idioventricular rhy thm (rate 
<40 bpm), accelerated idioventricular rh ythm (40< x <100), and 
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 85monomorphic/poly morphic ventricular tach ycardia >100 bpm (such as torsades de 
pointes).
Type IIsecond -degree (Mobitz II) AVblock.
Complete (third- degree) heart block.
ECG Findings That Qualify as Serious Adverse Events
Change in pattern suggestive of new m yocardial infarction. 
Sustained ventricular tachy arrhy thmias (>30 seconds’ duration).
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion.
Ventricular f ibrillation/flutter.
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience.
The enumerated list of major events of potential clinical concern are recommended as “alerts” or 
notifications from the core ECG laboratory to the investigator and [COMPANY_007] study team, and not to be 
considered as all inclusive of what to be reported as AEs/SAEs.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 8610.7. Appendix 7: Medical Device Incidents: Definition and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
Definitions of a Me dical Device Incident
The detection and documentation procedures described in this protocol apply  to all sponsor 
medical devices provided for use in the stud y (see Section 8.3.7 andSection 6.1.3 )for the list 
of sponsor medical devices).
Medical Device Incident Definition
A medical device incident is any  malfunction or deterioration in the characteristics 
and/or performance of a device as well as an y inadequacy in the labeling or the 
instructions for use which, directly or indirectl y, might lead to or might have led to 
the death of a participant/user/other person or to a serious deterioration in his/her 
state of health.
Not all in cidents lead to death or serious deterioration in health.  The 
nonoccurrence of such a result might have been due to other fortunate 
circumstances or to the intervention of healthcare personnel.
It is sufficient that:
An incident associated with a device happened.
AND
The incident was such that, if it occurred again, might lead to death or a serious 
deterioration in health.
A serious deterioration in state of health can include an y of the following:
Life-threatening illness;
Permanent impairment of body  function or permanent damage to bod y structure;
Condition necessitating medical or surgical intervention to prevent one of the above;
Fetal distress, fetal death, or an y congenital abnormality  or birth defects.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 87Examples of Incidents
A participant, user, ca regiver, or healthcare professional is injured as a result of a 
medical device failure or its misuse.
A participant’s investigational product is interrupted or compromised by  a medical 
device failure.
A misdiagnosis due to medical device failure leads to inappropriate treatment.
A participant’s health deteriorates due to medical device failure.
Documenting Medical Device Incidents
Medical Device Incident Documentation
Any medical device incident occurring during the study  will be documented in the 
partic ipant’s medical records, in accordance with the investigator’s normal 
clinical practice, and on the appropriate form of the CRF.
For incidents fulfilling the definition of an AE or an SAE, the appropriate 
AE/SAE CRF page will be completed as described in Appendix 3 .
The CRF will be completed as thoroughl y as possible and signed b y the 
investigator before transmittal to the sponsor or designee.
It is very  important that the investigator provides his/her assessment of causality  
(relationship to the medical device provided b y the sponsor) at the time of the 
initial AE or SAE report and describes an y corrective or remedial actions taken to 
prevent recurrence of the incident.
A remedial action is an y action other than routine mainte nance or servicing of a 
medical device where such action is necessary  to prevent recurrence of an 
incident.  This includes any  amendment to the device design to prevent 
recurrence.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 8810.8. Appendix 8: Country- Specific Requirements
There is no country  specific requirement of all the countries planned for this study .
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 8910.9. Appendix 9: Prohibited Concomitant Medications and Procedures
1.Any live attenuated vaccines.
2.DMARDs including small molecules , biologics and biosimilars with the except ion of :
methotrexate (as specif ied in Section [IP_ADDRESS] ).
leflunomide , anti -malarials and sulfasalazine (stable dose of at least 4 weeks).
Participants who are on DMARD therap y with the exception s noted above, the doses 
can be reduced or discontinued as per medical judgement. Initiation of additional 
DMARDs or increase dose of current DMARD therap y during the stud y is prohibi ted.  
A combination of no mo re than [ADDRESS_705615] :  
Small molecule DMARDs prohibited: Biologic/Biosimilar DMARDs prohibited:
azathioprine Abatacept
cyclophosphamide Anakinra
cyclosporine TNF inhibitors
Janus kinase (JAK) inhibitors Tocilizumab
tacrolimus (FK506) Rituximab
6 mercaptopurine (6 -MP)
3. Other investigational drugs or investigational biologics.
4. B- cell depleting therap y.
5.Plasma exchange therap y.
6.IV immunoglobulin (IVIG).
7.High potency , sustained release narcotics (see allowed opi[INVESTIGATOR_2438]/ narcotics in 
Section 6.5.2 ).
8.Intra -articular (IA) Corticosteroid Injections ( please also reference Rescue Therapy , 
Section 6.5.3 ):
Investigators should follow local standard of care where participants should 
receive no more than one injection per month and no more than three injections 
per year. 
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 9010.10. Appendix 1 0: New Yor k Heart Associated Functional Classification Criteria 
The table below describes the most commonly  used classification s ystem for heart failure, the 
[LOCATION_001] Heart Association (NYHA) Functional Classification.10  It places patients in one 
of four categories based on how much they  are limited during ph ysical activity . 
Class Functional Capacity: How a patient with cardiac disease feels during phy sical
activity .
I Patients with cardiac disease but resulting in no limitation of phy sical activity .  
Ordinary  physical activity  does not cause undue fatigue, palpi[INVESTIGATOR_332], dy spnea or 
anginal pain.
II Patients with cardiac disease resulting in slight limitation of phy sical activity .  
They  are comfortable at rest.  Ordinary  physical activity  results in fatigue, 
palpi[INVESTIGATOR_332], dy spnea or anginal pain.
III Patients with cardiac disease resulting in marked limitation of phy sical activity .  
They  are comfortable at rest.  Less than ordinary  activity  causes fatigue, 
palpi[INVESTIGATOR_332], dy spnea or anginal pain.
IV Patients with cardiac disease resulting in inability  to carry  on any  physical 
activity  without discomfort.  Sy mptoms of heart failure or the anginal syndrome 
may be present even at rest.  I f any  physical activity  is undertaken, discomfort 
increases.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 9110.11. Appendix 11: COVID -19 Pandemic Considerations 
Inresponse to the ongoing global pandemic COVID-19, and the increasing restrictions and 
concerns on public health, the following changes are being incorporated into the B5381012 
protocol to clarify  alternative solutions to accommodate study  procedures during the 
unpre ceden tedtime ( egthe COVID -19 pandemic ).  
The following alternative solutions are only acceptable during the COVID -19 pandemic :  
The PI  [INVESTIGATOR_541155]. Local law and regulations may  appl y.
For participants who have received stud y treatment, scheduled study visits may  be 
done remotel y.
Forstudy drug dispensation, study drugs may bedispensed viaacourier arranged by
[CONTACT_541188], thehome health care service oralternative transports as
agreed uponbetween siteandstudy participant.   Please besure alternative drug
dispensation is in accordance with applicable laws andregulations.   
A home health care service will be added as an option to scheduled study  visits after 
the Day  1/Week 0 Visit to: provide investigational product to study  participants , 
including administration of study  treatment, collect vital signs and specimens and/or 
processing of laboratory  tests as specified in the protocol.  In these cases, the 
investigator or designee must con tact the study  participants to collect adverse event 
(AE)/serious adverse event (SAE) information.  Investigator or designee should also 
confirm dosing data with the participant and record it in the site’s source or eDiary .  
Randomization atWeek 10may bedone off-site:
Bodyweight isrequired tobetaken atDay 1 oratScreening, whichever iscloser
totheWeek 10visit,   andwillbeused torandomize asstated intheprotocol.
Sites willneed tocallIWRStorandomize thestudy participant intoeither the
switching arm(PF-06410293) or non -switching arm(Humira) fortreatment.   
Once treatment assignment isreceived, sitemay dispense thestudy medication
anddeliver it totheparticipant asdescribed below.
Thehome health care service may beused tocollect specimens forsafety
evaluation, PK,ADA/NAb, vital signs andpossibly deliver study medication.
Dosing compliance confirmation should berecorded by[CONTACT_541189](s)/staff
remotely insite’s source documents orineDiary atthetime oftheremote visit.   
Dosing data must beentered timely intheeCRF.
AEs, contraception useandconcomitant medications will becollected by[CONTACT_541190](s)/staff remotely ,egby[CONTACT_541191].
For partici pant discontinuation reporting in the CRF: select the most appropriate 
status for discontinuation; if the discontinuation is associated with the current 
COVID -19 pandemic, enter “COVID -19” in the “Specify  Status” field.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 9210.12. Appendix 1 2: Abbreviations 
The foll owing is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
6-MP [ADDRESS_705616] aspartate aminotransferase
AUC area under the concentration -time curve
AUC  area under the concentration -time curve over the dosing interval
AV Atrioventricular
BA Bioavailability
BBS Biospecimen Banking S ystem
BE Bioequivalence
-hCG beta-human chorionic gonadotropin
BMI Body mass index
BP blood pressure
Bpm beats per minute
BUN blood urea nitrogen
Cav average concentration
CD Crohn's disease
CFR Code of Federal Regulations
CHF congestive heart failure
COVID -19 Coronavirus Disease 2019
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CL/F apparent clearance
Cmax maximum observed concentration
CMC Chemistry , Manufacturing, and Controls
CO 2 carbon dioxide (bicarbonate)
CONSORT Consolidated Standards of Reporting Trials
COX -[ADDRESS_705617] Rheumatism
FAP Final Approved Protocol
FDA [LOCATION_002] (US) Food and Drug Administration
FK506 Tacrolimus
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GGT gamma -glutamy l transferase
H Hour
HbA 1c hemoglobin A 1c
HBcAb hepatitis B core antibod y
HBsAb hepatitis B surface antibody
HBsAg hepatitis B surface antigen 
HCG human chorionic gonadotropin
HCL Hydrogen chloride
HCV hepatitis C
HCVAb hepatitis C antibody
PF-[ADDRESS_705618]
HIV human immunodeficiency virus
HPV human papi[INVESTIGATOR_541156] y
HS hidradenitis suppurativa
IA intra articular
IB investigator’s brochure
IC Interchangeability
ICD informed consent document
ICH International Council for Harmonisation
ID Identification
IFU Instruction for Use
IgG1 Immunoglobulin G1
IM Intramuscular
IMP investigational medicinal product
IND investigational new drug application
Inj injection 
INR international normalized ratio
IP investigational product
IP manual investigational product manual
IRB institutional review board
IRC internal review committee
IRT interactive response technology
ISR injection -site reaction s
ITT intent -to-treat
IUD intrauterine device
IUS intrauterine hormone -releasing s ystem
IVIG IV immunoglobulin
IWRS interactive Web -based response sy stem
JAK janus kinase inhibitor
LBBB left bundle branch block
LDAS low disease activity  state
LFT liver function test
mAb monoclonal antibody
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MedDRA Medical dictionary  for regulatory  activities
MnB Neisseria meningitidis serogroup B
Msec Millisecond
PF-06410293
Protocol B5381012Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 95Abbreviation Term
MTX Methotrexate
N/A not applicable
Nab neutralizing antibodies
NIMP noninvestigational medicinal product
NMSC Non-Melanoma Skin Cancer
NOAEL no-observed-adverse-effect level
NYHA [LOCATION_001] Heart Association
PACLs Protocol Administrative Clarification Letters
PCD primary completion date
PD pharmacodynamic(s)
PFS prefilled syringe
PFP pre-filled pen
PI [INVESTIGATOR_19959](s)
PS plaque psoriasis
PSA psoriatic arthritis
PT prothrombin time
PVC premature ventricular contraction/complex
QTc corrected QT
QTcF corrected QT (Fridericia method)
QFT QuantiFERON®- TB Gold In-Tube test
Qual qualitative
RA rheumatoid arthritis
RBC red blood cell
RNA ribonucleic acid
SAE serious adverse event
SAP statistical analysis plan
SC subcutaneous
SEER Surveillance, Epi[INVESTIGATOR_623], and End Results
SmPC Summary of Product characteristics
SMQ standardized MedDRA query
SoA schedule of activities
SOP standard operating procedure
SRSD single reference safety document
SToD study team on demand
S[LOCATION_003]R suspected unexpected serious adverse reaction
TB tuberculosis
TBili total bilirubin
TEAE treatment-emergent adverse event
Tmax time at which C maxoccurs
TNF Tumor necrosis factor
TP treatment periodsCCI
PF-[ADDRESS_705619] upper limit of normal
US [LOCATION_002]
USPI [INVESTIGATOR_541157]-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 9711.REFERENCES
1. Humira US Prescribing Information (USPI). [ADDRESS_705620] 2018. 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125057s409lbl.pdf 
Accessed on [ADDRESS_705621] 2018.
2. Humira (adalimumab) Summary of Product Characteristics (SmPC). 26 Jul 2018. 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/0004
81/human_med_000822.jsp&mid=WC0b01ac058001d124 Accessed on [ADDRESS_705622] DE,etal.  Adalimumab, afully human anti–tumor
necrosis factor α monoclonal antibody , for the treatment of rheumatoid arthritis in
patients taking concomitant methotrexate: theARMADA trial. Arthritis Rheum
2003;48:35-45.
4. Sampson HA, Munoz- Furlong A, Campbell RL , et al. Second s ymposium on the 
definition and management of anaph ylaxis: summary  report --Second National I nstitute 
of Allergy  and Infectious Disease/Food Allergy  and Anaphy laxis Network sy mposium. 
J Allergy  Clin Immunol 2006;117(2)(Feb):391 -7.
5. CDER and Center for Evaluation and Research.  Clinical Pharmacology  and 
Biopharmaceutics Review(s).  Application 125057/0, page 36. 
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/BLA_125057_S000_HUMI
RA_BIOPHARMR.PDF Accessed [ADDRESS_705623] 2018.
6. CDER and Center for Evaluation and Research.  Clinical Pharmacology  and 
Biopha rmaceutics Review(s).  Application 125057/0, page 43. 
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/BLA_125057_S000_HUMI
RA_BIOPHARMR.PDF Accessed [ADDRESS_705624].  May  2019.  Available: 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Gu
idances/UCM537135.pdf.
8. FDA Guidance for Industry , Scientific considerations in demonstrating biosimilarity  to 
a reference product. April 2 015. Available:
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Gui
dances/UCM291128.pdf .
9. FDA Guidance for Industry , Clinical Pharmacology  Data to Support a Demonstration of 
Biosimilarity  to a Reference Product.  December 2016.  
Available:https://www.fda.gov/media/[ZIP_CODE]/download .
10. [LOCATION_001] Heart Association Classification of Congestive Heart Failure. 
http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes
-of-Heart -Failure_UCM_306328_Article.jsp.
PF-06410293
Protocol B5381012
Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 9811. Hochberg MC, Chang RW, Dwosh I , et al.  The ACR 1991 revised criteria for the 
classification of global functional status in rheumatoid arthritis.  Arthritis Rheum 
1992;35:498 -502.